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Ph. D., Biomedical Sciences, University of New Mexico, 2011

Abstract
Oxidative stress and its damage resulting in carbonylation of proteins is known to take
place in the CNS tissue of multiple sclerosis patients and of mice with experimental
autoimmune encephalomyelitis (EAE), and has been implicated in the pathophysiology
of these diseases. In order to investigate the possible consequences of this protein damage
during acute myelin basic protein (MBP) -directed autoimmune neuroinflammation the
first goal of this thesis was to characterize oxidative stress and protein carbonylation,
including identification of the major oxidized protein species, in the Lewis rat model of
EAE. I discovered that there is significant oxidative stress in the spinal cord of EAE rats
characterized by reduced levels of glutathione, increased lipid peroxidation products, and
accumulation of protein carbonyls during the inflammatory stages of the disease. Using
two-dimensional oxyblot I was able to identify various CNS cytoskeletal proteins,
including the neurofilaments (NFH, NFM, and NFL) and β -tubulin, as major targets of
this oxidative damage. There are many possible fates for carbonylated proteins including
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accumulation, formation of high molecular weight aggregates and proteolysis.

The

specific fate likely depends not only on the particular species being oxidized but also on
the level of damage it sustains. Western blotting for the neurofilaments and β -tubulin
revealed that there is significant degradation of these cytoskeletal proteins during the
disease and that the level of specific oxidative damage to NFL changes during the disease
course. The second major objective of this thesis was to investigate the role of calpain
and the proteasome, which have been proposed to selectively degrade carbonylated
proteins, in the removal of these cytoskeletal proteins during neuroinflammation and to
examine whether oxidative modification of the proteins made them more susceptible to
degradation. This idea was tested by inhibiting calpain or the proteasome in EAE Lewis
rats by intrathecal injection of calpeptin or epoxomicin during the peak of clinical
disease. After inhibiting calpain, I found significant increases in total protein
carbonylation and in the amount of neurofilament proteins and β-tubulin that are spared
from degradation, but no changes are seen in the specific oxidation of any of these
protein species. Inhibition of the proteasome did not affect total protein carbonylation or
degradation, but did change the specific oxidation of NFM. These results suggest that (1)
calpain is the primary clearance mechanism of neurofilament and β-tubulin in acute EAE,
but that carbonylation of these proteins does not enhance their susceptibility to calpainmediated proteolysis and (2) the proteasome may contribute to removal of carbonylated
cytoskeleton, though it does not play a significant role in the axonal damage observed in
acute EAE.

This is the first study to investigate the relationship between protein

carbonylation and targeted degradation in vivo, and provides insight into the relationship
between oxidative stress and axonal damage during neuroinflammation.
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1. Introduction and Background
1.1 Multiple Sclerosis and its animal model Experimental Autoimmune
Encephalomyelitis (EAE)
Multiple Sclerosis (MS) is an inflammatory disorder of the CNS and is a leading cause of
neurologic disability in young adults. Believed to be autoimmune in nature, MS is
characterized by perivenular infiltration of lymphocytes and macrophages in the CNS
white matter with the ensuing development of well-defined areas of demyelination and
astrocytic proliferation and varying degrees of oligodendrocyte death and axonal damage
(Keegan & Noseworthy 2002). Neurologic disability in MS is attributed to pathological
changes (Kornek & Lassmann 1999). Most patients with MS (85%) have a relapsingremitting form (RR-MS), with periods of neurologic disability, termed “attacks,”
followed by complete recovery. RR-MS can transform into secondary progressive MS
(SP-MS), characterized by increasing irreversible neurologic decline with attacks
superimposed (Keegan & Noseworthy 2002). Axonal degeneration in MS is thought to
be a major component of the irreversible neurologic disability that patients experience
during the progressive stages of the disease. Although the cause of axonal transection is
not known, pathological studies in MS brains implicate inflammatory mediators as a
primary source. The number of transected axons, determined by identification of axonal
ovoids, is increased 13-fold in active compared to chronic lesions (Trapp et al. 1998).
This initial damage during inflammation has long lasting effects. Axonal density in
normal appearing white matter of the spinal cord is reduced up to 57% in SP-MS patients
(Lovas et al. 2000), and 50-80% in the spinal cord of paralyzed patients (Trapp et al.
1998).
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Experimental autoimmune encephalomyelitis (EAE) shares a number of clinical and
pathological features with MS, and is routinely employed to study the mechanistic bases
of disease and to test therapeutic approaches (Gold et al. 2000). Animal models show
similar association of inflammation as the primary cause of axonal damage. In Lewis rat
EAE, acute axonal pathology, measured by axonal staining for β -amyloid precursor
protein in active lesions, is present and correlates with the extent of macrophage
infiltration (Kornek et al. 2000). In a chronic EAE model, with repeated inflammatory
events in the spinal cord, no permanent neurologic disability was seen after the first
attack despite a 22% axonal loss (Wujek et al. 2002). After multiple attacks mild
permanent disability was seen with 28-48% axonal loss, and non-remitting paralysis was
associated with 43-59% axonal loss. Thus, the number of attacks correlated strongly with
both percent axonal loss and sustained disability. These studies support the notion that
compensatory mechanisms will allow for neurologic recovery despite damage to axons
during inflammatory events (in the relapsing-remitting stage MS) until a threshold level
of axonal damage is sustained, after which more permanent disabilities (seen in the
secondary-progressive MS) manifest themselves.
EAE, a widely-used animal model of MS, can be induced in a variety of
mammalian species by active immunization with myelin-specific antigens (e.g., myelin
basic protein (MBP), myelin proteolipid protein (PLP), myelin oligodendrocyte
glycoprotein (MOG)) or by adoptive transfer of T-cells from immunized animals into
naïve recipients (Day 2005). MBP-induced EAE in the Lewis rat, the animal model used
in this study, is an acute monophasic clinical disease that resolves spontaneously within 5
days of onset. At the peak of disease there are perivenular infiltrates of inflammatory
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cells within the spinal cord. There is, however, no demyelination of CNS axons, making
this an ideal model to study the neuroinflammatory aspects of MS. Inflammatory lesions
are the primary location of damaged axons in MS and EAE (Kornek et al. 2000).

1.2 Oxidative Stress and its role in MS and EAE
1.2.1 Oxidative stress and its resulting damage to cellular components
Oxidative stress occurs when reactive oxygen species are increased beyond the levels at
which cellular antioxidant defense systems can mitigate their damage to cellular
components (Mancuso et al. 2009). Oxidative stress and its resulting damage to cellular
structures are thought to be an important pathophysiological feature of MS and EAE
(reviewed in Gilgun-Sherki et al. 2004, LeVine 1992).

A number of reactive oxygen

species (ROS) are generated both intracellularly and extracellularly in MS and EAE
(LeVine 1992, Smith et al. 1999, Bizzozero 2009). The major ROS generated
extracellularly by infiltrating phagocytes and by activated microglia are hydrogen
peroxide (H2O2), hypochlorous acid (HClO) and peroxynitrite (ONOO-) (Smith et al.
1999). H2O2 is formed by non-enzymatic dismutation of superoxide, which is the product
of one-electron reduction of O2 via NADPH oxidase. H2O2 is a highly diffusible and
relatively unreactive molecule, and therefore it can rapidly enter cells. In the presence of
transition metals (Fe2+, Cu+), H2O2 readily decomposes into the highly reactive hydroxyl
radical (OH.) which can oxidize a large variety of macromolecules. Hypochlorite is a
stable and potent oxidant produced by reaction of H2O2 with chloride ions via
myeloperoxidase, an enzyme present in neutrophils and some types of monocytes. The
intracellular ROS (mostly O2.- and H2O2) are largely made by dysfunctional mitochondria
(Smith et al. 1999), though the contribution from other sources like xanthine oxidase,
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microsomal cytochrome P-450, and cyclo/lipooxygenases may be also significant.
Several processes that occur in MS and EAE, such as glutamate excitotoxicity, axonal
depolarization, and glutathione depletion, lead to mitochondrial damage and ROS
production (Smith et al. 1999). Of these processes, glutamate excitotoxicity is the most
important. Activated immune cells (macrophages and microglia) release large amounts of
glutamate, and excitotoxic damage has been shown to take place in both EAE (Pitt et al.
2000, Smith et al. 2000) and MS (Stover et al. 1997, Werner et al. 2001). The pathogenic
role of glutamate excitotoxicity in inflammatory demyelination is supported by three
major findings. First, the type of demyelinating lesions and axonal damage caused by
excitotoxins are histologically similar to those observed in MS (Matute 1998). Second,
the treatment of EAE mice with AMPA/kainate antagonists ameliorates the clinical
symptoms, increases oligodendrocyte survival and reduces dephosphorylation of NFH, an
indicator of axonal damage (Pitt et al. 2000, Smith et al. 2000). In addition,
administration of the glutamate antagonist riluzole has been shown to lessen the clinical
severity, inflammation, demyelination and axonal damage of EAE animals (GilgunSherki et al. 2003). Third, CSF levels of glutamate in MS show a positive correlation
with the severity and course of the disease (Barkhatova et al. 1998, Stover et al. 1997). It
is noteworthy that high quantities of glutamate may also be released in MS as
consequence of sustained, spontaneous, repetitive electrical discharges in demyelinated
(Kapoor et al. 1997) and injured axons (Stys 2005). However, regardless of the cellular
origin of this neurotransmitter, the prolonged activation of brain cells by glutamate
triggers membrane depolarization and influx of calcium, which in turn results in
mitochondrial production of ROS. The above studies indicate that ROS can be generated
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not only by inflammatory cells but also by dysfunctional mitochondria as the result of
glutamate excitotoxicity.
The occurrence of oxidative stress in tissues is concurrent with the reduced levels of
glutathione, a major cellular antioxidant, and the increase in lipid peroxidation products,
including 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), and acrolein. Lipid
peroxidation products have been found in both CSF and plasma of MS patients (Hunter et
al. 1985, Naidoo & Knapp 1992). Increased free radical activity and a decrease in both
antioxidants and major antioxidant enzymes have also been reported (Langemann et al.
1992, LeVine 1992). While oxidation of lipids and nucleic acids in these disorders has
been studied extensively, until recently protein oxidation has received little attention.
Protein carbonylation is an oxidative damage to proteins that occurs in many
neurodegenerative disorders such as Alzheimer’s disease (Aksenov et al. 2001),
Parkinson’s disease (Floor & Wetzel 1998) and amyotrophic lateral sclerosis (Ferrante et
al. 1997). Carbonylation of proteins can have deleterious effects on their biological
activity. For example, carbonylation of both actin and tubulin protein molecules can lead
to instability and depolymerization of the filaments (Yan & Sohal 1998). Our laboratory
has shown that protein carbonyls also build up in white matter and gray matter of MS
patients (Bizzozero et al. 2005b) and in murine EAE (Zheng & Bizzozero 2010a). In the
present study I aimed to characterize protein oxidation in MBP-induced EAE in the
Lewis rat, an animal model that mimics neuroinflammatory features of MS, and
investigate the mechanisms and consequences of this oxidative damage during
neuroinflammation.
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1.2.2 Mechanisms and implications of protein carbonylation
Carbonylation of proteins is an irreversible form of damage since there are no known
enzymatic mechanisms that can repair proteins once they become carbonylated
(Bizzozero 2009). Protein carbonyls are relatively difficult to induce compared to other
oxidative modifications and are considered to occur under conditions of severe or
prolonged oxidative stress (Dalle-Donne et al. 2003). Protein carbonyls are a useful
maker of oxidative stress because they are a permanent modification for the life of the
protein (Bizzozero 2009). Although the protein backbone and the side chains of most
amino acids are susceptible to oxidation, the non-enzymatic addition of aldehydes or
ketones to specific amino acid residues (i.e., carbonylation) constitutes the major and
most common oxidative alteration (Berlett & Stadtman 1997, Dalle-Donne et al. 2003,
Nystrom 2005).

Figure 1.1 Mechanisms of formation of protein-bound carbonyls.
(From Bizzozero O.A., Protein carbonylation in neurodegenerative and demyelinating CNS disease.
Handbook of Neurochemistry and Molecular Neurobiology. 2009. pp, 543-562)

Carbonyl groups can be introduced into proteins either by direct (oxidative) reaction of
ROS (e.g., hydrogen peroxide, lipid hydroperoxides) with protein side chains or the
6

protein backbone, or via indirect (non-oxidative) addition of reactive carbonyl species
(RCS) to Cys, His and Lys residues (Figure 1.1). RCS are carbonyl-containing molecules
resulting from the oxidation of lipids (e. g. 4-hydroxynonenal (4-HNE), malondialdehyde
(MDA), acrolein) or carbohydrates (e.g., glyoxal, methylglyoxal). When this oxidative
attack affects the protein backbone, either through alpha-amidation pathway (Figure 1.2)
or through oxidation of glutamyl side chains, the resulting peptide has an alpha-ketoacyl

Figure 1.2. Cleavage of the protein backbone via the α-amidation pathway.

Figure 1.3. Oxidation of the protein backbone through glutamyl side chain.
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derivative blocking its N-terminal amino acid (Berlett and Stadtman, 1997) (Figure 1.3).
The metal-catalyzed oxidation of the amino acid side chains of arginine, lysine, proline,
and threonine also result in protein carbonyls. Oxidative deamination reactions transform
prolyl and arginyl residues into glutamic semialdehyde (Figure 1.4) and lysyl residues
into aminoadipic semialdehyde (Figure 1.5). Oxidation of the secondary alcohol group of
threonine residues results in its conversion to α-amino-β-ketobutyryl (Figure 1.6).

Figure 1.4. Oxidative deamination reaction mechanism of arginine and proline side chains
resulting in transformation to glutamic semialdehyde.
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Figure 1.5. Oxidative deamination reaction mechanism of lysine side chains.

Figure 1.6. Direct oxidative attach of the threonine side chain.

As indicated above, protein carbonyls can also arise from indirect mechanisms.
These reactions are not the result of direct attack by reactive oxygen species. Instead, as
lipid and carbohydrates are oxidized the carbonyl containing byproducts of these
reactions can attach to the protein.

As previously discussed, peroxidation of
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polyunsaturated fatty acids (PUFA) forms the aldehyde lipid peroxidation products 4HNE and MDA. 4-HNE is capable of reacting with lysine, histidine, and cysteine,
residues. Malondialdehyde reacts with protein amino groups. Other reactive carbonyl
species, including reducing sugars and their oxidation products (e. g., glyoxal,
methylglyoxal), can participate in non-oxidative reactions to introduce carbonyls into
proteins.
While both direct and indirect oxidative mechanisms can introduce carbonyls into
proteins, the relative contribution of the different mechanisms is still controversial.
While inhibition of lipid peroxidation will reduce the amount of protein carbonyls in
diseased tissues, but modified amino acids resulting from direct pathways have been
found to be the major modification in human brain tissue. Increased mitochondrial
production of hydrogen peroxide and superoxide using glutathione depletion in rat brain
slices increases protein carbonyls and is not reversed using RCS scavengers (Zheng &
Bizzozero 2010c).

Furthermore, cerebellar proteins from EAE mice at the peak of

neurological disease do not contain acrolein, 4-HNE or MDA adducts, as determined by
western blot with specific antibodies against these moieties (Zheng & Bizzozero 2010a).
These findings suggest that direct oxidation of amino acids is the chief mechanism
resulting in protein carbonyls.
Cytoskeletal proteins are established targets of protein carbonylation in many
diseases including CNS disorders (Aksenov et al. 2001, Muntane et al. 2006). As
described in Chapter 2, I observed that β-actin, β-tubulin, and the three neurofilament
chains are the major targets of carbonylation in acute EAE.

More importantly,

carbonylation of cytoskeletal proteins is known to have deleterious effects on the
10

macromolecule structures. For instance, actin filaments and microtubules both destabilize
or disassemble upon oxidation of their protein components (Banan et al. 2001, Banan et
al. 2004, Dalle-Donne et al. 2001, Neely et al. 2005, Ozeki et al. 2005). The secondary
structure of neurofilaments is also altered when the individual proteins become
carbonylated (Gelinas et al. 2000) often leading to the formation of dense aggregates
(Smith et al. 1995). Oxidized neurofilament proteins also have increased propensity
toward proteolysis (Troncoso et al. 1995). One of the aims of this thesis is to investigate
potential consequences of protein carbonylation on the metabolic stability of cytoskeletal
proteins in EAE.

1.2.3 Accumulation of protein carbonyls in the CNS of MS patients and EAE animals
Protein carbonylation is an irreversible form of damage resulting from severe or
prolonged oxidative stress conditions (Dalle-Donne et al. 2003), which occurs in many
neurodegenerative disorders including Alzheimer’s disease (Aksenov et al. 2001),
Parkinson’s disease (Floor & Wetzel 1998) and amyotrophic lateral sclerosis (Ferrante et
al. 1997). Our discovery that protein carbonyls are augmented in MS (Bizzozero et al.
2005b) and in mice with EAE (Zheng & Bizzozero 2010a), suggests that this type of
chemical modification may also play a critical pathophysiological role in inflammatory
demyelinating diseases. A major goal of this study was to investigate whether protein
carbonyls accumulate during the inflammatory period in acute EAE and whether those
carbonylated proteins persist in CNS tissue upon resolution of the single
neuroinflammatory event that characterizes MBP-induced EAE in the Lewis rat. As
described in Chapter 2, I observed that protein carbonylation increases coincident with
the peak neurologic disability in the spinal cord tissue of EAE rats, but the animals are

11

able to clear the carbonylated proteins from their CNS tissue when neurologic symptoms
disappear. Because carbonylation is irreversible, the reduction in protein carbonyls
indicates that proteolytic mechanisms are working to remove these damaged proteins
from the spinal cord.

1.3 Proteolytic mechanisms involved in axonal damage and protein carbonyl
removal
Magnetic resonance spectroscopic imaging studies closely link the amount of axonal
damage to the neurologic disability seen in individual MS patients (De Stefano et al.
1998, Matthews et al. 1998). Significant loss of axons, up to 60%, in early and chronic
MS lesions has been reported (Lovas et al. 2000, Mews et al. 1998). Axons are
particularly susceptible to injury during neuroinflammation, although neuronal cell
bodies are also damaged (Coleman & Perry 2002). Complete axonal transection leading
to the build up of neurofilament proteins in amyloid precursor protein (APP)-positive
ovoids has also been observed in MS lesions (Ferguson et al. 1997, Trapp et al. 1998).
Although axonal damage can be found in normal appearing white matter, much of the
damage to axons is localized in areas of high microglia, macrophage and cytotoxic Tlymphocyte activity. Upon activation these cells all produce ROS causing oxidative
damage to axons in the inflammatory lesions.

Additionally, the high metabolic

requirements of neurons increase the propensity of oxidative damage to axonal proteins
by mitochondrial sources of ROS (Neumann 2003). In this study I investigate damage
and proteolysis of major axonal proteins, focusing on cytoskeletal proteins. As described
in chapter 2, I show that there is significant degradation of major axonal cytoskeleton
proteins and that these proteins are also carbonylated.
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There are multiple possible fates for carbonylated proteins, and the outcome likely
depends on the specific protein being carbonylated, as well as the level of oxidative
damage it sustains. The concentration of carbonylated proteins within cells is normally
extremely low; although even moderate increases in carbonylation can have tremendous
effects on protein function, aggregate formation, or metabolic stability. Maintenance of
low carbonylation level is achieved through the action of several proteolytic systems that
preferentially digest oxidized proteins. It has been proposed that targeted digestion is a
consequence of unfolding as a result of the oxidative modification (Grune et al. 2004).
The core 20S proteasome is known to catalyze the degradation of oxidized proteins in an
ATP- and ubiquitin-independent manner, and is thought to be the primary clearance
mechanism for carbonylated proteins in cells (Grune et al. 1997). For example, during
myocardial ischemia/reprofusion oxidized actin is removed by the 20S proteasome
(Divald & Powell 2006). Oxidized protein aggregates accumulate during aging, and it has
been proposed that this may be a direct consequence of reduced proteosomal activity with
aging (Agarwal & Sohal 1994, Bota & Davies 2002). Proteasomal activity is also reduced
in chronic murine EAE and may contribute to accumulation of protein carbonyls in that
model (Zheng & Bizzozero 2010b). However, other proteases have been implicated in
the hydrolysis of oxidized proteins as well. For example, the calcium-dependent cysteine
protease calpain has been shown to preferentially degrade oxidized neurofilament over
non-oxidized protein in vitro (Troncoso et al. 1995). In culture, calcium import into cells
both activates calpain and stimulates carbonylation of mitochondrial apoptosis inducible
factor protein (AIF); in this system calpain-mediated proteolysis of AIF occurs at a rate
five times faster than degradation of non-oxidized AIF (Norberg et al. 2010). Calcium
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homeostasis is altered during EAE and it is known that calpain is activated in neurons
(Guyton et al. 2005), glia and inflammatory cells (Shields & Banik 1998) coincident with
inflammation in the Lewis rat model.
While many proteins become more susceptible to degradation by cellular
proteases upon carbonylation of one or more residues (Stadtman 1990), other oxidized
proteins become more resistant to proteolysis. For example, mildly carbonylated
aconitase is proteolytically degraded but when carbonyl modifications affect more amino
acid residues high-molecular-weight aggregates form, and unlike the mildly oxidized
species these aggregates are not susceptible to break down by the mitochondrial Lon
protease (Bota & Davies 2002). Additionally, carbonylated proteins can inhibit the
proteases that degrade them, and carbonylation of the proteases themselves impairs their
function (Friguet et al. 1994, Grune et al. 2004, Shacter 2000). Ultimately, it is this
phenomenon that likely causes the long-term accumulation of carbonylated species in
diseased tissues. As their concentration within cells builds up, carbonylated proteins tend
to cross-link forming high-molecular-weight aggregates, which are both cytotoxic and no
longer susceptible to proteolysis (Nie et al. 2007, Smith et al. 1995).
While there is significant evidence for preferential proteolysis of carbonylated
proteins in vitro, the function and relative contributions of these proteolytic mechanisms
has not been adequately demonstrated in vivo.

For this reason I tested two major

proteolytic systems, calpain and the 20S proteasome, known to preferentially digest
oxidatively modified proteins. By inhibiting these systems in the CNS tissue of EAE
animals I sought to investigate which, if either, of these pathways was responsible for
clearance of carbonylated proteins during neuroinflammation. As described in chapter 3,
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modest inhibition of calpain led to accumulation of protein carbonyls in the CNS tissue,
but small reduction in proteasome activity did not significantly affect carbonyl levels. My
results suggest that the accumulation of protein carbonyls after calpain inhibition appears
to be a consequence of overall sparing of cytoskeletal proteins, which are major targets of
carbonylation, rather than the blocking of a pathway that specifically targets oxidized
proteins for removal.

1.4 Hypothesis
I proposed to test the hypothesis that oxidative stress conditions occur in acute
experimental autoimmune encephalomyelitis (EAE), an animal model of multiple
sclerosis, and lead to increased oxidation (carbonylation) of cytoskeletal proteins.
Oxidation of these proteins augments their susceptibility to proteolytic degradation and
thereby contributes to the axonal damage that is characteristic of inflammatory
demyelinating disorders.

1.5 Rationale for a study of protein oxidation and its consequences in EAE
This study built upon findings in our laboratory that protein carbonyls accumulate in the
CNS tissue of people with multiple sclerosis. The goal of this thesis work was to
characterize oxidative stress and its proteolytic consequences in the Lewis rat EAE model
for MS. This animal model mimics the myelin-directed neuroinflammatory events in
MS, not the chronic demyelination seen in later disease stages.
The study in Chapter 2 was designed to characterize markers oxidative stress in
EAE spinal cord tissue throughout the disease course, and to determine if EAE displays
oxidative damage to proteins similar to that seen in MS. I sought to determine whether
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changes in protein carbonylation levels occur during the course of EAE and to identify
specific proteins that are carbonylated in this disorder. The focus was on cytoskeletal
proteins because (1) their abundance in cells makes them common targets of various ROS
and RCS (Dalle-Donne et al. 2006), and (2) they are major targets of oxidation in MS
(Bizzozero 2007). The results clearly show that the oxidative stress conditions generated
during the course of MBP-induced EAE in the Lewis rat are sufficient to cause protein
carbonylation. I found that cytoskeletal proteins, including neurofilaments, β-tubulin, βactin, and GFAP were major targets of protein carbonylation, and neurofilaments and βtubulin were degraded during the disease course. This chapter also shows that the
percentage of neurofilament light chain protein (NFL) that is carbonylated changes
during the disease course. A decrease in the percentage of oxidized NFL suggests that
carbonylation of this protein may trigger proteolytic degradation of these molecules in
EAE.
The goal of the studies described in Chapter 3 was to explore the possibility of a
link between the carbonylation and degradation of cytoskeletal proteins during EAE. The
claim that oxidative protein damage targets proteins for degradation has been asserted in
the literature and is generally accepted as true. However, the studies that address the
topic use either cell-free or cell culture systems. I used the EAE model to investigate the
relationship between cytoskeletal oxidation and degradation in vivo, and to identify the
proteolytic machinery responsible for cytoskeletal degradation.

To this end, EAE

animals were treated with inhibitors for calpain or the proteasome for 48 hours during the
peak disease activity. By inhibiting the cellular mechanisms of proteolytic degradation I
was able to investigate the contribution of the different degradation pathways to
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cytoskeletal loss and to accumulation of carbonylated protein species. In order to address
whether carbonylated proteins are preferentially degraded, I determined the specific
proportion of carbonylated cytoskeletal proteins in inhibitor-treated and vehicle-treated
EAE animals. This approach assesses the relative degradation of oxidized and normal
cytoskeletal proteins. If indeed my hypothesis were correct, then inhibiting a pathway
that preferentially degrades oxidized proteins would lead to accumulation of carbonylated
proteins and higher specific oxidation of cytoskeletal species. Treating EAE animals via
intrathecal (i.t.) injection of the calpain inhibitor calpeptin prevented significant
degradation of neurofilaments and β-tubulin proteins and led to an overall increase in the
accumulation of protein carbonyls in the spinal cord tissue. However, I was unable to
detect changes in the specific oxidation of any of these proteins in the calpeptin-treated
animals compared to vehicle-injected EAE rats. Treatment with the proteasome inhibitor
epoxomicin did not significantly alter cytoskeletal levels or specific oxidation. These
findings suggest that calpain plays a critical role in removal of cytoskeletal proteins in
EAE, but does not preferentially digest carbonylated proteins.
Chapter 4 recaps the data presented in chapters 2 and 3. In this chapter I work to
bring the findings of this thesis together and put the work into context, assessing the
overall contribution of my thesis to understanding the mechanisms that lead to
cytoskeletal protein carbonylation and digestion during inflammation in EAE. Taken
together the findings of this thesis provide valuable insights into the relationship
beteween neuroinflammation and oxidation of neuronal cytoskeleton and into the
mechanisms involved in removal of damaged cytoskeletal proteins. These studies, to the
best of my knowledge, are also the first to explore the role of different proteolytic
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mechanisms in the removal of carbonylated proteins in an in vivo system and to
demonstrate that oxidative damage to proteins is only a minor player in their degradation
during acute inflammation. This work also shows that neither calpain nor the proteasome
appear to preferentially target carbonylated cytoskeletal proteins for removal.
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2.1 Abstract
Protein carbonylation, the non-enzymatic addition of aldehydes or ketones to specific
amino acid residues, has been implicated in the pathophysiology of multiple sclerosis
(MS). In this study we investigated whether protein carbonyls (PCOs) also accumulate in
the spinal cord of Lewis rats with acute experimental autoimmune encephalomyelitis
(EAE). Western blots analysis after derivatization with dinitrophenyl hydrazine (oxyblot)
showed elevated protein carbonylation at the time of maximal clinical disability. During
the same period glutathione levels were substantially reduced, suggesting a causal
relationship between these two markers. In contrast, lipid peroxidation products
accumulated in EAE spinal cord well before the appearance of neurological symptoms.
Carbonyl staining was not restricted to inflammatory lesions but present throughout the
spinal cord particularly in neuronal cell bodies and axons. By 2-dimensional-oxyblot we
identified several cytoskeletal proteins, including β -actin, GFAP and the neurofilament
proteins as the major targets of carbonylation. These findings were confirmed by pulldown experiments, which also showed an increase in the number of carbonylated β-actin
molecules and a decrease in that of oxidized neurofilament proteins in EAE. These data
suggest the possibility that oxidation targets neurofilament proteins for degradation,
which may contribute to axonal pathology observed in MS and EAE.

2.2 Introduction
Experimental autoimmune encephalomyelitis (EAE) shares a number of clinical and
pathological features with MS, and is routinely employed to study the mechanistic bases
of disease and to test therapeutic approaches (Gold et al. 2000). This animal model of MS
can be induced in a variety of mammalian species by active immunization with myelin-
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specific antigens (e.g., MBP, PLP, MOG) or by adoptive transfer of T-cells from
immunized animals into naïve recipients (Day 2005). MBP-induced EAE in the Lewis
rat, the animal model used in this study, is an acute monophasic clinical disease that
resolves spontaneously within 5 days of onset. At the peak of disease there are
perivenular infiltrates of inflammatory cells within the spinal cord. There is, however, no
demyelination of CNS axons, making this an ideal model to study the neuroinflammatory
aspects of MS.
In recent years a significant body of experimental evidence has accumulated
demonstrating that oxidative stress is a major player in the pathogenesis of both MS and
EAE (for reviews, see Gilgun-Sherki et al. 2004, LeVine 1992). While oxidation of lipids
and nucleic acids in these disorders has been studied extensively, protein oxidation has
received little attention. The non-enzymatic addition of aldehydes or ketones to specific
amino acid residues (i.e. carbonylation) constitutes the major and most common
oxidative alteration (Berlett & Stadtman 1997, Dalle-Donne et al. 2003, Nystrom 2005).
Carbonyl groups can be introduced into proteins either by direct (oxidative) reaction of
ROS (e.g., hydrogen peroxide, lipid hydroperoxides) with protein side chains or indirect
(non-oxidative) addition of reactive carbonyl species (RCS) to Cys, His and Lys residues.
RCS are carbonyl-containing molecules resulting from the oxidation of lipids (e.g., 4hydroxynonenal, malondialdehyde (MDA), acrolein) or carbohydrates (e.g., glyoxal,
methylglyoxal). Protein carbonylation is an irreversible form of damage that results from
severe or prolonged oxidative stress conditions (Dalle-Donne et al. 2003), which occurs
in many neurodegenerative disorders including Alzheimer’s disease (Aksenov et al.
2001), Parkinson’s disease (Floor & Wetzel 1998) and amyotrophic lateral sclerosis
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(Ferrante et al. 1997). Our discovery that protein carbonyls are augmented in MS
(Bizzozero et al. 2005a) suggests that this type of chemical modification may also play a
critical pathophysiological role in inflammatory demyelinating diseases.
There are multiple possible fates for carbonylated proteins; the outcome likely
depends on the specific protein being carbonylated as well as the level of oxidative
damage it sustains. The concentration of carbonylated proteins within cells is normally
extremely low; although even moderate increases in the carbonylation can have
tremendous effects on protein function, aggregate formation, or metabolic stability.
Maintenance of low carbonylation level is achieved through the action of several
proteolytic systems that preferentially digest oxidized proteins. The core 20s proteasome
is known to catalyze the degradation of oxidized proteins in an ATP- and ubiquitinindependent pathway, and is thought to be the primary clearance mechanism for
carbonylated proteins in cells (Grune et al. 1997). However, other proteases have been
implicated in the hydrolysis of oxidized proteins as well. For example, the calciumdependent cysteine protease calpain has been shown to preferentially degrade oxidized
neurofilament over non-oxidized protein (Troncoso et al. 1995). While many proteins
become more susceptible to degradation by cellular proteases upon carbonylation of one
or more residues (Stadtman 1990), other oxidized proteins become more resistant to
proteolysis. Additionally, carbonylated proteins can inhibit the proteases that degrade
them, and carbonylation of the proteases themselves impairs their function (Friguet et al.
1994, Shacter 2000). Ultimately it is this phenomenon what likely causes the
accumulation of carbonylated species in diseased tissues. As their concentration within
cells build up, carbonylated proteins tend to crosslink forming high-molecular-weight
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aggregates, which are both cytotoxic and no longer susceptible to proteolysis (Nie et al.
2007, Smith et al. 1995).
The present study was designed to determine if EAE displays oxidative damage to
proteins similar to that seen in MS. We sought to determine whether changes in protein
carbonylation levels occur during the course of EAE and to identify specific proteins that
are carbonylated in this disorder. Our focus was on cytoskeletal proteins because (1) their
abundance in cells makes them common targets of various ROS and RCS (Dalle-Donne
et al. 2006), and (2) they are major targets of oxidation in MS (Bizzozero et al. 2007).
The results clearly show that the oxidative stress conditions generated during the course
of MBP-induced EAE in the Lewis rat are sufficient to cause protein carbonylation and
that this process may trigger proteolytic degradation of oxidized cytoskeletal proteins. To
the best of our knowledge this is the first study demonstrating protein carbonylation in
EAE. A preliminary account of these findings has been presented in abstract form
(Smerjac & Bizzozero 2006, Smerjac & Bizzozero 2007).

2.3 Materials and Methods
2.3.1 Induction of Experimental Autoimmune Encephalomyelitis (EAE)
Housing and handling of the animals as well as the euthanasia procedure were in strict
accordance with the NIH Guide for the Care and Use of Laboratory Animals, and were
approved by the Institutional Animal Care and Use Committee. Seven-week-old male
Lewis rats were purchased from Harlan Bioproducts (Indianapolis, IN) and housed in the
UNM-animal resource facility. EAE was induced in these animals as described by
Schaecher et al. 2002) with slight modifications. Briefly, rats received two subcutaneous
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injections into the lower back area of 100µl each containing 200 mg/ml of guinea pig
spinal cord homogenate plus 280 µg/ml of guinea pig myelin basic protein (Sigma, St.
Louis, MO) in saline mixed with complete Freund's adjuvant (CFA) supplemented with 1
mg/ml of heat killed Mycobacterium tuberculosis H37Ra (Chondrex Inc; Redmond,
WA). Control animals were given CFA without myelin antigens. Two hours after EAE
induction, all animals received an i.p. injection of 2 µg of pertussis toxin (List Biological
Laboratories; Campbell, CA) in 100 µl of saline. Animals were weighed and examined
daily for the presence of neurological signs. At prescribed days post-injection (DPI)
animals were euthanized by decapitation. Spinal cords were dissected and either fixed
with methacarn or homogenized in PEN buffer (20 mM sodium phosphate pH 7.5, 1 mM
EDTA and 0.1 mM neocuproine) containing 2 mM 4,5 dihydroxy-1,3 benzene disulfonic
acid and 1 mM dithiothreitol (DTT). Protein homogenates were stored at -80˚C until use.
Protein concentration was assessed with the Bio-Rad DCT protein assay (Bio-Rad
Laboratories; Hercules, CA) using bovine serum albumin as standard.

2.3.2 Determination of glutathione (GSH)
The amount of non-protein thiols, of which > 90% is GSH (Vitvitsky et al. 2006), was
determined with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB; Sigma). Briefly, an aliquot
of the spinal cord homogenate prepared in PEN buffer without DTT was mixed with an
equal volume of 2% sulfosalicylic acid to precipitate the proteins. After centrifugation at
10,000g for 15 min, the supernatants were mixed with 0.2M sodium phosphate buffer pH
7.5 containing 0.3 mM DTNB, 10 mM EDTA and 1% SDS and incubated for 15 min at
room temperature. Absorbance was measured at 412 nm using a Hewlett-Packard 8452-A
Diode Array Spectrophotometer. The amount of thiol groups was calculated using a
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molar extinction coefficient of 13,600 cm-1 for the thionitrobenzoate anion (Riddles et al.
1979).

2.3.3 Measurement of lipid peroxidation
Lipid peroxidation was assessed by measuring the amount of thiobarbituric acid reactive
substances (TBARS), which are byproducts of lipid peroxidation, in the tissue
homogenates (Ohkawa et al. 1979). One-hundred-µl aliquots (~500µg of protein) were
mixed with 25µl of 2% (w/v) butylated hydroxytoluene and 875µl of 1% (w/v)
thiobarbituric acid (Aldrich; Milwaukee, WI) prepared in 10% (w/v) trichloroacetic acid.
Samples were incubated for 20 min at 90˚C. Aggregated material was removed by
centrifugation at 10,000g for 15 min and the absorbance of the supernatant was measured
at 532 nm. The amount of TBARS was calculated using a standard curve prepared with
1,1,3,3-tetraethoxypropane (Aldrich).

2.3.4 Assessment of protein carbonylation by western blotting
Protein carbonyl groups were measured with the OxyBlot™ protein oxidation detection
kit (Intergen Co., Purchase, NY), following the protocol provided by the manufacturer. In
brief, proteins (5µg) were incubated with 2,4-dinitrophenyl-hydrazine to form the 2,4dinitrophenyl (DNP) hydrazone derivatives. Proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted to polyvinylidene
difluoride (PVDF) membranes. DNP-containing proteins were then immunostained using
rabbit anti-DNP antiserum (1:500) and goat anti-rabbit IgG conjugated to horseradish
peroxidase (HRP) (1:2000). Blots were developed by enhanced chemioluminescence
(ECL) using the Western Lightning ECL™ kit from Perkin-Elmer (Boston, MA). The
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developed films were scanned in a Hewlett Packard Scanjet 4890 and the images
quantified using the Scion Image for Windows, version Alpha 4.0.3.2 (Scion
Corporation, Frederick, MD).

2.3.5 Two-dimensional gel electrophoresis of carbonylated spinal cord proteins
DNP-labeled proteins were also dissolved in isoelectric focusing (IEF) buffer (8M urea,
2% CHAPS, 50mM DTT and 0.2% (w/v) Bio-Lyte® 3/10 ampholytes). Proteins were
absorbed on 11cm-long ReadyStrip IPG® strips (pH range 3-10 non-linear; BioRad) and
IEF was carried out at 30,000 V-hr. IEF strips were equilibrated for 10 min in 375mM
Tris-HCl buffer pH 8.8 containing 6M urea, 2% SDS, 20% glycerol with 130mM DTT,
followed by 10 min the same buffer containing 135mM iodoacetamide instead of DTT.
Proteins were separated on 10% Criterion™ pre-cast gels (BioRad) followed by western
blotting carried out as described above. Blots were probed with anti-DNP antibodies,
then stripped and probed with antibodies against specific cytoskeletal proteins. Spot
matching between blots was performed using The Discovery Series PDQuest 2-D
Analysis Software Version 7.0.1 (BioRad).

2.3.6 Identification of carbonylated proteins
Tissue proteins (0.5mg), dissolved in 200 µl 2% SDS, were incubated at room
temperature with 5 mM biotin-hydrazide (Sigma). After 60 min, proteins were
precipitated with 1 ml of acetone at -20˚C and collected by centrifugation at 10,000g for
10 min. Pellets were washed three times with 1 ml of acetone-water (3:1, v/v) and
dissolved in 100 µl of 100 mM Tris-HCl buffer pH 7 containing 1% SDS and 100 mM
NaCl. The solutions were diluted 20-fold with 100 mM NaCl and centrifuged at 10,000g
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for 10 min to remove any aggregated material. The supernatants were then incubated for
1 h at 20˚C with 50µl of streptavidin-agarose (Sigma) previously equilibrated in 100 mM
Tris-HCl pH 7.6 containing 0.05% SDS and 100mM NaCl (buffer A). The resin was
washed 5-times with 500 µl of buffer A, 4-times with buffer A containing 1M NaCl, and
once with buffer A without NaCl. Bound-proteins were eluted from the resin with 100 µl
of SDS-sample buffer containing 1% 2-mercaptoethanol. Aliquots from the total and
bound fractions were separated by SDS-PAGE on 10% polyacrylamide gels and blotted
against PVDF membranes. Blots were probed with antibodies against NFH (1:1000,
rabbit polyclonal; Chemicon, Temecula, CA), NFM (1:4000, rabbit polyclonal,
Chemicon), NFL (1:1000, mouse monoclonal, Chemicon), β -tubulin (1:1000, mouse
monoclonal; Sigma), GFAP (1:5000, rabbit polyclonal; Dako, Carpinteria, CA) and β actin (1:1000, mouse monoclonal; Abcam Inc., Cambridge, MA), followed by incubation
with the appropriate HRP-conjugated secondary antibody. Blots were developed by ECL
as described above.

2.3.7 Statistical Analysis
Results were analyzed for statistical significance with Student's unpaired t test or
ANOVA utilizing the GraphPad Prism® (version 4) program (GraphPad Software Inc.,
San Diego, CA).

2.4 Results
2.4.1 Characteristics of Lewis rat EAE animals
EAE in male Lewis rats was induced as described under “Materials and Methods.”
Symptoms were graded according to the following scale: 0, no symptoms; 1, tail
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weakness; 1.5, clumsy gait; 2, hind limb paresis; 2.5, partial hind limb dragging; 3, hind
limb paralysis; 3.5, hind limb paralysis with fore limb paresis; 4, complete paralysis; 5,
moribund. Following immunization with MBP, Lewis rats experienced an acute and
monophasic inflammation of the spinal cord resulting in clinical disability. Neurological
symptoms begin at 9-11 DPI, peaking at 12-13 DPI, with full recovery by 16 DPI (Table
2.1). CFA-injected control and EAE rats were sacrificed on days 7, 9, 10, 11, 13, and 15
after injection. Animals injected with antigen that did not show symptoms after 12 DPI
were excluded from our analysis. Spinal cord sections from vertebrae T6-L2 were
removed; portions from each animal were homogenized for biochemical analysis or fixed
in methacarn for IHC. Since none of the biochemical parameters corresponding to CFA
injected control animals measured in this study changed during the course of the
experiment, they were combined to obtain the average control values.

2.4.2 Oxidative stress occurs in the spinal cord of EAE rats: oxidation of glutathione and
lipids
To establish the occurrence of oxidative damage in EAE, we measured the levels of GSH
in the spinal cords of the affected animals throughout the disease course. As shown in
Figure 2.1A, GSH levels in EAE spinal cords was 58% and 72% of control values at 10
and 11DPI, respectively, indicating that the CNS of the affected animals is subjected to
considerable oxidative stress. Normal GSH levels were observed prior to 10 DPI and
after 11 DPI.
Lipid oxidation, another commonly used marker of oxidative stress conditions,
was determined by measuring the amount of thiobarbituric acid reactive substances
(TBARS) in spinal cords. As depicted in Figure 2.1B, the level of TBARS augmented in
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EAE at all time points examined (i.e. 7–15 DPI), demonstrating carbonyl stress
conditions in the EAE spinal cord before and after the period of clinical disability.

2.4.3 Oxidative stress damage increases protein carbonylation in EAE
We recently reported that protein carbonylation in brain slices can be stimulated by
depleting GSH and/or inducing lipid peroxidation (Bizzozero et al. 2006). Because both
of these changes take place during the course of EAE, we thought that protein carbonyls
might also accumulate in this disorder. The presence of protein carbonyls in the spinal
cord tissue of CFA-injected control animals and EAE rats throughout the disease course
was investigated using the oxyblot technique. A representative western blot detecting
protein carbonyls (i.e. oxyblot) of one control and 5 EAE spinal cords from different DPI
is shown in Figure 2.2A. At 11 and 13 DPI, there is a clear increase in the carbonyl
content of several protein bands from EAE rat spinal cords relative to control.
Quantitative analysis of the oxyblots revealed that at 11 and 13 DPI, total protein
carbonyl levels in EAE spinal cords increase by 70% relative to control spinal cords
(Figure 2.2B) returning to control values at 15 DPI. Since carbonylation is an irreversible
protein modification, the above results indicate that a clearance mechanism to eliminate
these damaged proteins must operate in the disease tissue.
The accumulation of carbonyls in EAE spinal cords was also assessed using the
DNPH-based IHC procedure that we have recently developed to determine the
anatomical distribution of PCOs in brain sections (Bizzozero et al. 2006). In this case,
however, detection of PCOs was performed by immunofluorescence utilizing a TRITClabeled secondary antibody. Figure 2.3 shows the IHC distribution of carbonyls in the
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spinal cord of a control and an EAE animal at 11 DPI. The amount of carbonyls in both
the gray matter (GM) and white matter (WM) from the CFA-injected control is relatively
low. There is an overall increase in protein carbonyls in both WM and GM from EAE
spinal cords, as opposed to localization around inflammatory lesions. Motor neurons and
axons (arrows) were the most intensely stained structures in the diseased tissue, and this
distribution is reminiscent to that of cytoskeletal elements. Validation of this IHC
technique was performed by omitting the DNPH-treatment, the anti-DNP antibody or the
secondary anti-rabbit IgG antibody (not shown). In addition, we carried out a positive
control in which carbonyls are generated by incubating spinal cords sections with
FeSO4/H2O2 and a specificity control in which endogenous carbonyls are removed by
incubation with NaBH4.

2.4.4 Oxidation levels of β-actin and NFL change during disease
The particular staining pattern for carbonyls prompted us to investigate whether the major
cytoskeletal proteins are subjected to carbonylation. Identification of carbonyl-containing
proteins was initially carried out by spot matching DNP-labeled proteins on a 2-D gel
with those of specific cytoskeletal elements. As shown in Figure 2.4, β-actin, GFAP and
the neurofilament proteins are among the major carbonylated targets in EAE.
Quantification of the extent of oxidation of these species was performed by the pulldown/western blot procedure recently used in our laboratory to identify carbonylated
cytoskeletal proteins during GSH depletion (Bizzozero 2007, Bizzozero et al. 2006). To
this end, protein carbonyls from control and 13 DPI EAE spinal cord homogenates were
first converted into biotinylated residues by reaction with biotin-hydrazide. Biotincontaining proteins were then isolated with streptavidin-agarose and analyzed by western
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blotting employing antibodies against the three neurofilament chains, β-tubulin, β-actin,
and GFAP. The results show that all six of these proteins are targets of carbonylation,
with significant changes in the amount of oxidized NFL and β -actin (Table 2.2). It is
important to note that, while total protein oxidation increases in EAE (Figure 2.2), the
number of molecules that are carbonylated for specific proteins may increase or decrease
depending on whether or not the modified species is selectively degraded during the
course of the disease.

2.4.5 Neurofilaments and β-tubulin are degraded in EAE spinal cord
The integrity of CNS cytoskeletal network was investigated by western blotting of
control and EAE spinal cord proteins. Figure 2.5A shows representative western blots of
the three neurofilament chains, β-tubulin, β-actin and GFAP from control and EAE spinal
cord (9 and 13 DPI). Figure 2.5B depicts the relative level of these proteins (normalized
for coomassie blue staining) compared to average control values throughout the disease
course. There are significantly lower levels of NFH, NFM, NFL, and β-tubulin in EAE
compared to CFA-treated control. Since cytoskeletal proteins are very stable (Li & Black
1996, Nixon & Logvinenko 1986), this finding clearly indicates that their disappearance
from the EAE spinal cord is due to increased degradation rather than diminished
synthesis. A decrease in NFL protein at 10-12 DPI has been reported previously (Shields
& Banik 1998) and is believed to be indicative of increased calpain activity in EAE
spinal cord. GFAP and β-actin are not degraded, and the increase in GFAP protein at 15
DPI corroborates previous reports of gliosis beginning at 14 DPI in this model (Aquino et
al. 1988). The specific oxidation (percentage of total protein modified by carbonylation)
of b-actin (a protein that is not degraded) is higher in EAE, whereas that of NFL
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decreases in EAE. This finding suggests that, while b-actin is resistant to proteolysis, the
oxidized neurofilament may be preferentially degraded in this disorder.

2.5 Discussion
In this study we have characterized oxidative stress conditions that occur in MBPinduced EAE in the Lewis rat by measuring established markers for oxidative damage
throughout the disease course. We discovered that the concentration of free GSH in the
spinal cord of EAE rats is greatly decreased at 10-11 DPI, returning to normal values at
13 DPI. There are several, and not mutually exclusive, reasons underlying the reduction
of free GSH in the diseased spinal cord. These include (1) oxidation of GSH to GSSG
with hydrogen peroxide or lipid hydroperoxides via a reaction catalyzed by glutathione
peroxidase; (2) conjugation of GSH with reactive α,β-unsaturated aldehydes derived form
lipid peroxidation (e.g., acrolein, 4-hydroxynonenal) by a reaction catalyzed by
gluthathione S-transferase; (3) reduced cellular uptake of cysteine, required for GSH
synthesis, due to high levels of glutamate (Sagara & Schubert 1998); (4) decreased
activity of enzymes involved in the GSH synthesis (e.g., glutathione synthetase) and/or
recycling of GSSG (e.g., glutathione reductase); and (5) diminished amount of NADPH,
which is needed for GSSG reduction. Preliminary results in our laboratory have shown
that the amount of total glutathione (i.e. GSH + GSSG) in EAE spinal cord is also
reduced, suggesting that the disappearance of GSH cannot be simply attributed to its
oxidation. However, regardless of the mechanism responsible for the decrease in lowmolecular-weight thiols, GSH levels return to normal values as inflammation subsides
and animals recover.
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TBARS, the most commonly used measurement for lipid peroxidation, detects
dialdehydes (mostly MDA) resulting from breakdown of lipid hydroperoxides and
endoperoxides (Esterbauer et al. 1991). In contrast to the reduction of GSH levels, which
parallels disease activity, the concentration of TBARS in the EAE spinal cords is elevated
at every time point measured (i.e. 7-15 DPI). This result indicates that oxidative stress
takes place prior to the appearance of inflammatory lesions in the spinal cord of EAE
animals, a pathological process that correlates temporally with neurological symptoms
(Schaecher et al. 2002). The presence of TBARS in 15 DPI animals, which are
recovering neurologically, may be due to continued ROS generation or more likely to the
persistence of dialdehydes in the tissue (MDA t½ = 2 days) (Aldini et al. 2007).
The most important finding in this study is that several carbonylated protein
species accumulate in the spinal cord of EAE rats at 11–13 DPI. The degree and
distribution of protein carbonylation present during autoimmune neuroinflammation was
unexpected and indicates that the oxidative stress conditions in this model are very
severe. Nonetheless, in this acute animal model of MS there appears to be a mechanism
that eliminates these damaged proteins and bring carbonylation to control levels as the
inflammatory process subsides. Indeed, it is believed that the accumulation of
carbonylated proteins is a multifaceted process that takes into account both the rate of
oxidation (dependent on both ROS formation and antioxidant levels) and the rate of
proteolysis of the damaged proteins (Sayre et al. 2005). It will be important to know if
repeated tissue injury would result in the long-term accumulation of oxidized proteins as
seen in multiple sclerosis (Bizzozero et al. 2005a), and ongoing studies are addressing
this issue in chronic animal models of MS.
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Since ROS have variable but still relatively short half-lives (10-9 s for hydroxyl
radicals, 10-6 s for superoxide, 10-3 s for peroxynitrite, 100 s peroxyl radicals and 102 s
for hydrogen peroxide) (Reth 2002), they normally damage targets that are in close
proximity to their source. Thus, if ROS in EAE spinal cords were generated mostly by
inflammatory cells, one would expect to find accumulation of protein carbonyls near the
inflammatory foci. Instead, we discovered that protein carbonyls are not circumscribed to
inflammatory lesions but accumulate throughout the spinal cord. This more generalized
carbonyl increase, staining multiple cell types including neurons, suggests that the origin
of ROS is likely metabolic. We have recently shown that total or even partial depletion of
GSH with diethyl maleate or 1,2-bis(2-chloroethyl)-1-nitrosourea results in abundant
protein carbonylation by a process involving mitochondrial production of ROS
(Bizzozero et al. 2006). While other cellular/subcellular sources of ROS cannot be
excluded, it is tempting to speculate that a similar mechanism takes place in EAE.
Supporting this idea are the facts that (1) there is mitochondrial damage and augmented
superoxide production in EAE and MS (Kalman et al. 2007) and (2) protein carbonyls do
not increase until after this antioxidant is depleted. The lack of protein carbonylation in
the presence of sustained RCS production is noteworthy and suggests that carbonylation
of proteins in EAE takes place via a direct mechanism and not indirectly by reaction with
dialdehydes (MDA, glyoxal, methyl glyoxal). In this regard, we have recently found that,
while dependent on lipid peroxidation, the carbonylation of cytoskeletal proteins during
depletion of glutathione probably occurs via lipid hydroperoxides rather than RCS
(Bizzozero et al. 2007).
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Another major finding in this study is the identification of several prominent
cytoskeletal proteins as targets of carbonylation in EAE. Cytoskeletal proteins are
established targets of protein carbonylation in many diseases including several CNS
disorders (Aksenov et al. 2001, Muntane et al. 2006). More importantly, carbonylation of
cytoskeletal proteins is known to have deleterious effects on the macromolecule
structures. For instance, actin filaments and microtubules both destabilize and
disassemble upon oxidation of their protein components (Banan et al. 2001, Banan et al.
2004, Dalle-Donne et al. 2001, Neely et al. 2005, Ozeki et al. 2005). The secondary
structure of neurofilaments is also altered when the individual proteins become
carbonylated (Gelinas et al. 2000), often leading to the formation of dense aggregates
(Smith et al. 1995).
In the present study, we have demonstrated that neurofilament proteins and β tubulin are extensively degraded in the EAE spinal cord, which likely causes alterations
in the cytoskeletal network. We have also observed that the specific oxidation of NFL
protein decreases in EAE, suggesting the possibility that oxidized neurofilament may be
preferentially degraded in this disease.

Although the heavy and medium chain

neurofilament proteins do not show changes in the specific oxidation at the 13 DPI time
point analyzed, variations in the susceptibility of these oxidized high molecular weight
neurofilament chains to degradation or aggregate formation may reconcile these
differences.

Additionally, the more rapidly formation of newly synthesized, and

therefore unoxidized, light chain neurofilament could contribute to the lower specific
oxidation at this time point. It is well known that proteolysis of carbonylated proteins in
cells under conditions of oxidative stress aids in preventing formation of large aggregates
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that could be cytotoxic (Davies & Shringarpure 2006, Shringarpure et al. 2001). The 20s
proteasome has been shown to selectively recognize and degrade oxidized proteins
(Grune et al. 1997, Pacifici et al. 1993, Rivett 1985), and upon its inhibition carbonylated
proteins do indeed accumulate (Lee et al. 2001). Calpain is also believed to be
responsible for neurofilament degradation in EAE (Shields & Banik 1998), but it is
unclear if this calcium-activated protease has preference for oxidized over native
polypeptides. Studies using proteasome and calpain inhibitors in EAE have primarily
focused on abatement of neurological symptoms without looking at specific proteins that
are protected from proteolysis (Guyton MK 2005, Hassen et al. 2006, Hosseini et al.
2001, Vanderlugt et al. 2000). Whether calpain, the proteasome, or a combination of
these proteolysis pathways is responsible for the degradation of carbonylated
neurofilament proteins in EAE is currently under investigation through use of specific
protease inhibitors in vivo. Recognizing the triggers for neurofilament degradation may
help us to understand the mechanisms of axonal degeneration during neuroinflammation.
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2.8 Tables and Figures
Table 2.1 Characteristics of disease in EAE animals
Number of days
post-induction
(DPI) of EAE

Number
of CFA
controls

Number of
animals that
developed EAE

Clinical Score
at sacrifice

7

1

0/3

3 = Grade 0

9

1

1/3

2 = Grade 0
1 = Grade 1.5

10

1

4/4

1 = Grade 3
1 = Grade 3.5
2 = Grade 4

11

5

9/9

3 = Grade 3
5 = Grade 3.5
1 = Grade 4

13

4

6/6

1 = Grade 2
4 = Grade 3
1 = Grade 3.5

15

3

4/4

1 = Grade 0
1 = Grade 1
1 = Grade 1.5
1 = Grade 3

Table 2.2 Specific oxidation of cytoskeletal proteins in control and EAE spinal cord

NFH
NFM
NFL
β-Tubulin
β-Actin
GFAP

Control
(% oxidized)
0.87 ± 0.09
0.24 ± 0.04
0.19 ± 0.04
0.08 ± 0.04
0.39 ± 0.09
1.87 ± 0.49

EAE (13 DPI)
(% oxidized)
1.71 ± 0.80
0.32 ± 0.04
0.08 ± 0.04 *
0.17 ± 0.06
0.76 ± 0.06 *
0.63 ± 0.38

Spinal cord homogenates from control and EAE (13 DPI) animals were derivatized with
biotin hydrazide and carbonylated proteins were isolated with streptavidin-agarose as
described in Materials and Methods. Total and bound fractions were analyzed by SDSPAGE followed by western blotting for six cytoskeletal proteins (3 neurofilament chains,
β-tubulin, β-actin, and GFAP). Specific oxidation (percentage of total protein modified
by carbonylation) is reported. Data was analyzed for statistical significance using t-test,
(*) p<0.05. β -actin showed increased carbonylation, whereas NFL had less oxidation
indicating the oxidized NFL may be degraded.
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Figure 2.1 Temporal profile of glutathione oxidation and lipid peroxidation in EAE spinal cord

(A) Free glutathione (GSH) levels in EAE spinal cord homogenates through disease
course measured using DTNB (see Materials and Methods). Data is represented as a
percent of average control GSH levels (8.8 ± 1.3 nmol GSH/mg protein). (B) Lipid
peroxidation was assessed by measuring TBARS as described in Materials and Methods
in spinal cord homogenates through disease course. EAE values are expressed as a
percentage of the average control value (0.48 ± 0.07 nmol TBARS/mg protein). GSH and
TBARS data were analyzed for statistical significance using a one-way ANOVA with
Dunnett’s multiple comparison post-test to determine statistical significance from control,
(**) p<0.01, (***) p<0.001. Lower glutathione at 10 -11 DPI points to considerable
oxidative stress in the CNS during onset of neurological symptoms. Increase in TBARS
at 7-15 DPI indicates carbonyl stress throughout the disease course.
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Figure 2.2 Protein carbonyls in the spinal cord of EAE rats increase during disease course

Spinal cord homogenates from control and EAE animals were derivatized with 2,4
dinitrophenylhydrazine then separated by SDS-PAGE. Carbonylated proteins were
determined using western blotting as described in Materials and Methods. (A)
Representative blot showing one control and 5 EAE animals sacrificed at a range of days
post injection (DPI). (B) Protein carbonyls (PCO) were tracked throughout the disease
course and are expressed as a percentage of the average carbonylation in control spinal
cords. Mean carbonyl levels (line) and the value for individual animals are shown at
various DPI. Data was analyzed for statistical significance using one-way ANOVA with
Dunnett’s multiple comparison post-test to determine statistical significance from control,
(**) p<0.01. Carbonylated protein species accumulate in the spinal cord of animals with
acute EAE at 11 and 13 DPI and return to control levels at 15 DPI indicating a clearance
mechanism for removal of oxidized species.
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Figure 2.3 Immunohistochemical localization of protein carbonyls in the rat spinal cord of EAE
animals

Carbonyls in thoracic spinal cord sections of a control and an EAE rat (score = 3.0) were
detected by immunohistochemistry as described in Materials and Methods. Images show
carbonyls the spinal cord ventral horn. Both neuronal cell bodies and axons are heavily
stained in the EAE sample (arrows and insets). The carbonyls increase is seen
throughout the spinal cord tissue, not localized around lesions. Tissue sections were
treated with Fe/H2O2 to generate carbonyls (positive control) or NaBH4 to block
endogenous carbonyls (negative control).
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Figure 2.4 Two-dimensional Oxyblot analysis of EAE spinal cord proteins

Spinal cord homogenates from EAE animals were derivatized with 2,4dinitrophenylhydrazine. Proteins were separated by 2-D-gel electrophoresis and blotted
to PVDF membranes. Membranes were immunostained with anti-DNP, then stripped
and re-probed with antibodies against the major cytoskeletal proteins. Cytoskeletal
proteins on anti-DNP blots were identified by spot matching using BioRad PD-Quest
software. The major carbonylated targets in EAE include β-actin, GFAP and the
neurofilament proteins.
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Figure 2.5 Levels of cytoskeletal proteins in EAE spinal cord

Spinal cord homogenates from control and EAE animals (5 µg protein) were separated by
SDS-PAGE followed by western blotting. Membranes were immunostained with
antibodies against six cytoskeletal proteins (3 neurofilament chains, β -tubulin, β -actin,
and GFAP). (A) Representative blot with 3 control and 3 EAE samples prepared from
animals at 9 and 13 DPI are shown. (B) Levels of each cytoskeletal protein were tracked
throughout the disease course and values are expressed as a percentage of the average
protein level in control spinal cords. Values for individual animals as well as the mean
value (line) are shown at each DPI. Data were analyzed for statistical significance using
one-way ANOVA with Dunnett’s multiple comparison post-test to determine statistical
significance from control, (*) p<0.05, (**) p<0.01. Neurofilaments and β -tubulin are
degraded in the disease, which is possibly a consequence of oxidative damage to these
proteins.
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3.1 Abstract
Recent work from our laboratory has shown that various CNS cytoskeletal proteins are
major targets of protein carbonylation in acute EAE. We also demonstrated that several
of these oxidative targets, including all three neurofilament chains and β -tubulin, are
degraded in the spinal cord during the peak of neurological disease. We hypothesized
that oxidative damage could be targeting these cytoskeletal proteins to get degraded by
one of two mechanisms responsible for the clearance of carbonylated proteins, the
calcium-dependent cysteine protease calpain or the 20S proteasome. The present study
was designed to investigate the role of calpain and the proteasome in the removal of these
cytoskeletal proteins and to test whether oxidative modification of the proteins made
them more susceptible to degradation. Calpain or proteasome activity was inhibited in
EAE Lewis rats by intrathecal injection of calpeptin or epoxomicin, respectively, during
the peak of clinical disease.

Biochemical analyses of spinal cord homogenates

investigated the effect of inhibition on total protein carbonylation, degradation of the
neurofilaments and β-tubulin, and changes in the percentage of these cytoskeletal proteins
that were carbonylated. After inhibiting calpain, we found significant increases in total
protein carbonylation and in the amount of neurofilament proteins and β-tubulin that were
spared from degradation, but no changes were seen in the specific oxidation of any of
these protein species. Inhibition of the proteasome did not affect total protein
carbonylation or degradation. These results suggest that calpain-mediated proteolysis
plays a role in the increased clearance of cytoskeletal proteins seen in acute EAE and that
oxidized and non-oxidized NF proteins are equally susceptible to digestion by this
calcium-activated protease.
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3.2 Introduction
A significant body of experimental evidence has accumulated recently demonstrating that
oxidative stress is a major player in the pathogenesis of both MS and EAE (GilgunSherki et al. 2004, LeVine 1992, Bizzozero 2009). Carbonylation, the non-enzymatic
addition of aldehydes or ketones to specific amino acid residues, is one of the primary
modifications to proteins under severe or prolonged oxidative stress conditions (Berlett &
Stadtman 1997, Dalle-Donne et al. 2003, Nystrom 2005). Protein carbonyls are an
irreversible form of protein damage (Dalle-Donne et al. 2003) occurring in many
neurodegenerative disorders including Alzheimer’s disease (Aksenov et al. 2001),
Parkinson’s disease (Floor & Wetzel 1998), amyotrophic lateral sclerosis (Ferrante et al.
1997) and multiple sclerosis (Bizzozero et al. 2005).
Concentrations of carbonylated proteins in cells are normally very low, but even
small changes in the percentage of oxidized proteins or the number of oxidative
modifications on a molecule can lead to the formation of protein aggregates, alter their
ability to function, or influence their metabolic stability.

A number or proteolytic

systems that preferentially degrade oxidized proteins operate in cells in order to keep the
cellular levels of protein carbonylation low. The core 20S proteasome degrades oxidized
proteins in an ATP- and ubiquitin-independent manner, and is believed to be the main
mechanism clearing carbonylated proteins in cells (Grune et al. 1997). Reduced activity
of the 20S proteasome does lead to accumulation of protein carbonyls in chronic EAE
(Zheng & Bizzozero 2010b).

There is evidence that other proteases preferentially

hydrolyze oxidized proteins as well. The calcium-dependent cysteine protease calpain has
been shown to preferentially degrade oxidized neurofilament over non-oxidized protein
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in a cell-free system (Troncoso et al. 1995). Calpain has also been shown to be an
important proteolytic pathway for cytoskeletal proteins in the CNS (Banik & Shields
2000) and its activity is elevated in both chronic (Hassen et al. 2008) and acute EAE
(Shields et al. 1998).
EAE shares a number of clinical and pathological features with MS, and is
routinely employed to study the mechanistic bases of disease and to test therapeutic
approaches (Gold et al. 2000).

MBP-induced EAE in the Lewis rat, the animal model

used in this study, is an acute monophasic clinical disease that resolves spontaneously
within 5 days of onset. At the peak of disease there are perivenular infiltrates of
inflammatory cells within the spinal cord. There is, however, no demyelination of CNS
axons, making this an ideal model to study the neuroinflammatory aspects of MS.
Previous studies in our laboratory have shown accumulation of protein carbonyls during
the peak of neurological symptoms in acute EAE (Smerjac & Bizzozero 2008). Protein
carbonyl levels return to normal levels after neuroinflammation and neurologic deficits
subside, indicating that proteolytic mechanisms are working to clear these damaged
proteins from CNS tissue. The peak of neurologic disease in acute EAE also coincides
with damage to the cytoskeletal protein network as seen by the significant degradation of
all three neurofilament chains and β-tubulin.
The present study was designed to identify the proteolytic activity leading to
cytoskeletal protein digestion in EAE and whether oxidative damage to those species
targets them for specific degradation. Our focus was on cytoskeletal proteins because
they are targets of oxidation in MS (Bizzozero 2007) and EAE (Smerjac & Bizzozero
2008, Zheng & Bizzozero 2010a). The specific oxidation of certain cytoskeletal proteins
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in acute EAE changes during the course of the disease, suggesting preferential targeting
of the oxidized species for degradation (Smerjac & Bizzozero 2008). Results presented
herein show that calpain plays a critical role in the proteolysis of neurofilament and
tubulin proteins during acute neuroinflammation. Inhibition of calpain activity during the
peak of disease leads to accumulation of oxidized protein species, but does not change
the specific oxidation levels of any of the neurofilament proteins or β-tubulin. Reducing
the activity of the 20S proteasome does not affect total protein carbonylation or
cytoskeletal protein levels, but does lead to accumulation of oxidized NFM. These
results suggest that while the proteasome may contribute to removal of oxidized proteins,
calpain is the main protease involved in degradation of the cytoskeleton and does not
preferentially target oxidized cytoskeletal proteins species in acute EAE. To the best of
our knowledge this is the first study using inhibition of calpain or the 20S proteasome to
investigate mechanisms of preferential degradation of oxidized proteins in vivo.

3.3 Materials and Methods
3.3.1 Induction of Experimental Autoimmune Encephalomyelitis (EAE)
Housing and handling of the animals, as well as the euthanasia procedure, were in strict
accordance with the NIH Guide for the Care and Use of Laboratory Animals, and were
approved by the Institutional Animal Care and Use Committee. Seven-week-old male
Lewis rats were purchased from Harlan Bioproducts (Indianapolis, IN) and housed in the
UNM-animal resource facility. EAE was induced in these animals as described
previously (Smerjac & Bizzozero, 2008). Rats were weighed and examined daily for the
presence of neurological signs. Animals were euthanized by decapitation 48 hours after
i.t. injection. Spinal cords segments L1-L3 were dissected and homogenized in HEN
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buffer (25 mM HEPES pH 7.5, 1 mM EDTA and 0.1 mM neocuproine) containing 2 mM
4,5 dihydroxy-1,3 benzene disulfonic acid and 1 mM dithiothreitol (DTT). Protein
homogenates were stored at -80˚C until use. Protein concentration was assessed with the
Bio-Rad DCT protein assay (Bio-Rad Laboratories; Hercules, CA) using bovine serum
albumin as standard.

3.3.2 Acute lumbar puncture and intrathecal drug delivery
Intrathecal (i.t.) drug injections were conducted when rats displayed the first signs of
clinical disease using the technique described by Milligan et al. (2005). An injection
catheter was inserted under brief isoflurane anesthesia (1–2% in oxygen). Here, a 25 cm
PE-10 catheter (attached by a 30-gauge sterile needle to a sterile, 50 µL glass Hamilton
syringe) was marked 7.7 cm from the open end. Under light anesthesia, the dorsal pelvic
area was shaved and cleaned with 70% alcohol. An 18-gauge sterile needle with the
plastic hub removed was inserted between lumbar vertebrae L5 and L6. The open end of
the PE-10 catheter was inserted via the 18-gauge needle and threaded to the 7.7 cm mark
allowing for intrathecal PE-10 catheter-tip placement at the T12 – L1 junction. Injections
consisted of 4 µL of DMSO containing either 4µg of calpeptin (Enzo Life Sciences, Inc.),
4 µg of epoxomicin (Cayman Chemical Company, Ann Arbor, MI) or no drug (vehicle),
with a 5 µl post 0.9% sterile, isotonic saline flush. The PE-10 catheter was immediately
withdrawn and the 18-gauge needle was removed from the L5-L6 inter-vertebral space.
Rats were then placed in their home cage and observed during recovery from anesthesia.
This acute injection method took 2–3 min to complete, and rats showed full recovery
from anesthesia within 10 min.
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3.3.3 Calpain activity assay
Calpain activity was determined in EAE spinal cords homogenates using a fluorescence
assay (Hassen et al. 2006). Spinal cord homogenates (100 µg protein) were diluted to 2
mg/mL in HEN buffer and membrane-bound calpain was removed prior to the assay by
centrifugation at 10,000 xg for 25 min. Next, 25 µL of the soluble fraction was incubated
with the substrate Suc-Leu-Leu-Val-Tyr-AMC in 100mM KCl, 10mM CaCl2, 25mM
HEPES, pH 7.5. The incubation was carried out in the absence and presence of 0.4
µg/µL calpeptin. Calpain activity was calculated as the difference in fluorescence
intensity at 460nm between the samples with and without inhibitor using an excitation
wavelength of 380nm.

3.3.4 Proteasome activity assay
Proteolytic activity of the 20S proteasome was determined in EAE spinal cord
homogenates using a similar fluorescence assay (Rodgers & Dean 2003). Briefly, 50µg
of protein were incubated for 1h at 25˚C with 50µM of the 7-aminomethyl-4-coumarin
(AMC)-labeled peptide Suc-Leu-Leu-Val-Tyr-AMC (for chymotrypsin-like activity) in
the absence or presence of 10µM clasto-lactacystin-β-lactone (Enzo Life Sciences,
Plymouth Meeting, PA). The activity of the 20S proteasome was calculated as the
difference in fluorescence intensity at 460nm between the samples with and without
inhibitor using an excitation wavelength of 380nm.

3.3.5 Assessment of protein carbonylation by western blotting
Protein carbonyl groups were measured with the OxyBlot™ protein oxidation detection
kit (Intergen Co., Purchase, NY), following the protocol provided by the manufacturer. In
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brief, proteins (5µg) were incubated with 2,4-dinitrophenyl-hydrazine to form the 2,4dinitrophenyl (DNP) hydrazone derivatives. Proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted to polyvinylidene
difluoride (PVDF) membranes. DNP-containing proteins were then immunostained using
rabbit anti-DNP antiserum (1:500) and goat anti-rabbit IgG conjugated to horseradish
peroxidase (HRP) (1:2000). Blots were developed by enhanced chemioluminescence
(ECL) using the Western Lightning ECL™ kit from Perkin-Elmer (Boston, MA). The
developed films were scanned in a Hewlett Packard Scanjet 4890 and the images
quantified using the Scion Image for Windows, version Alpha 4.0.3.2 (Scion
Corporation, Frederick, MD).

3.3.6 Assessment of cytoskeletal protein levels by western blotting
Aliquots (5 µg) from spinal cord homogenates were separated by SDS-PAGE on 10%
polyacrylamide gels and blotted against PVDF membranes. Blots were probed with
antibodies against NFH (1:1000, rabbit polyclonal; Chemicon, Temecula, CA), NFM
(1:4000, rabbit polyclonal, Chemicon), NFL (1:1000, mouse monoclonal, Chemicon),
and β -tubulin (1:1000, mouse monoclonal; Sigma), followed by incubation with the
appropriate HRP-conjugated secondary antibody. Blots were developed by ECL and
quantified as described above.

3.3.7 Identification of carbonylated proteins
Tissue proteins (1mg), dissolved in 200 µl 2% SDS, were incubated at room temperature
with 5 mM biotin-hydrazide (Sigma). After 60 min, proteins were precipitated with 1 mL
of acetone at -20˚C and collected by centrifugation at 10,000 xg for 10 min. Pellets were
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washed three times with 1 mL of acetone-water (3:1, v/v) and dissolved in 100 µL of 50
mM Hepes pH 7.5 containing 1% SDS and 100 mM NaCl. The solutions were diluted 20fold with 100 mM NaCl and centrifuged at 10,000 xg for 10 min to remove any
aggregated material. The supernatants were then incubated for 1 h at 20˚C with 50µL of
streptavidin-agarose (Sigma) previously equilibrated in 50 mM Hepes pH 7.5 containing
0.05% SDS and 100mM NaCl (buffer A). The resin was washed 5-times with 500 µL of
buffer A, 4-times with buffer A containing 1M NaCl, and once with buffer A without
NaCl. Bound-proteins were eluted from the resin with 100 µ L of SDS-sample buffer
containing 1% 2-mercaptoethanol. Aliquots from the total and bound fractions were
separated by SDS-PAGE on 10% polyacrylamide gels and blotted against PVDF
membranes. Blots were probed with antibodies against NFH, NFM, NFL, and β-tubulin
followed by incubation with the appropriate HRP-conjugated secondary antibody. Blots
were developed by ECL and quantified described above.

3.3.8 Statistical Analysis
Results were analyzed for statistical significance with Student's unpaired t-test or oneway ANOVA using IBM® SPSS® Statistics program (version 19.0.0).

3.4 Results
3.4.1 Neurological symptoms of EAE rats are not altered by intrathecal administration of
inhibitors
EAE in male Lewis rats was induced as described under “Materials and Methods.”
Symptoms were graded according to the following scale: 0, no symptoms; 1, tail
weakness; 1.5, clumsy gait; 2, hind limb paresis; 2.5, partial hind limb dragging; 3, hind
limb paralysis; 3.5, hind limb paralysis with fore limb paresis; 4, complete paralysis; 5,
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moribund. Following immunization with MBP, Lewis rats experienced an acute and
monophasic inflammation of the spinal cord resulting in clinical disability. As in previous
studies in our lab, the onset of neurological symptoms began at 9-11 days post
immunization (DPI) (Smerjac & Bizzozero 2008). The first day animals started
exhibiting neurological disease, clinical score 1 or greater, an i.t. injection was performed
as described in “Materials and Methods.” Animals injected with antigen that did not show
symptoms on 11 DPI were excluded from our analysis. Rats were treated with DMSO
(vehicle), the calpain inhibitor calpeptin, or the 20S proteasome inhibitor epoxomicin.
Animals were monitored for clinical disease for 48 hours after i.t. injection and then
sacrificed. Clinical disease at time of i.t. injection for the 3 groups did not show any
statistical difference, [F(2, 32) = 0.783, p = 0.466]. The disease course after i.t. injection
was not altered by inhibitor treatment (average clinical score at sacrifice, [F(2, 32) =
0.602, p = 0.554]). EAE rats were sacrificed on days 11 and 13 post EAE induction, 48
hours after i.t. injection. Spinal cord sections from vertebrae L1 – L3 were removed and
homogenized for biochemical analysis.

3.4.2 In vivo inhibitor treatment reduces calpain or proteasome activity in spinal cords of
EAE rats
The aim of this study was to investigate the mechanism of cytoskeletal protein
degradation in the spinal cord of EAE Lewis rats and determine whether oxidative
damage in the form of protein carbonyls led to preferential degradation. This question
was approached by inhibiting two potential degradation pathways: the calcium-dependent
cysteine protease calpain and the 20S proteasome. Calpeptin, a membrane-permeable
inhibitor that targets both m-calpain and µ-calpain (Saito & Nixon 1993), was used to
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inhibit calpain activity in the EAE spinal cord. We chose a dose of 4-µg of calpeptin, or
20-23 µg/kg, per animal, based on preliminary studies in our laboratory showing that i.t.
injections of this dosage to inhibit calpain activity by 29 – 33% in non-EAE animals.
Inhibition levels were reached 4 hours after i.t. injection and remained steady up to 48
hours post injection. A 2 µg/kg dose showed no significant inhibition of calpain activity
and a 200 µg/kg did not offer significantly higher inhibition than the chosen dose (data
not shown). Epoxomicin has been used for proteasome inhibition in the spinal cord in a
chronic pain model (Ossipov et al. 2007). It is quite specific for the 20S proteasome
inhibiting the chymotrypsin-like activity and reducing the trypsin-like and caspase-like
catalytic rates (Meng et al. 1999).

Preliminary studies with a dose of 4 µg

epoxomicin/animal yielded inhibition of proteasome activity in the range of 33-43% from
4 hours after i.t. injection remaining steady at 48 hours post injection. A 10x higher dose
did not show significantly higher proteasome inhibition (data not shown).
EAE animals were injected intrathecally with epoxomicin, calpeptin or the
vehicle DMSO alone at 9 – 11 DPI. Forty-eight hours after i.t. injection animals were
sacrificed and the L1 – L3 segments of the spinal cord were dissected and homogenized
for biochemical analysis.

Proteasome activity was measured in the spinal cord

homogenates from each animal using a fluorescence proteasome activity described in
“Materials and Methods” and is expressed as a percentage of the average proteasome
activity in the vehicle-treated EAE animals (Figure 3.1A).

Proteasome activity in

epoxomicin-treated EAE rats was significantly reduced to 76.4% ± 8.7% (Mean ± SEM)
of that in vehicle-treated animals while calpeptin treatment did not affect proteasome
activity (111.8% ± 21.5%). Calpain activity was measured in the supernatants of the
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spinal cord homogenates as described in “Materials and Methods.” As shown in Figure
3.1B, calpain activity was significantly reduced in calpeptin-treated animals to 78.3% ±
8.3% of the levels of vehicle-treated EAE animals, while epoxomicin treatment did not
affect calpain activity (106.3% ± 12.4%). It should be noted that inhibition of both the
proteasome and calpain in EAE animals was not as effective as the inhibition seen in
non-EAE animals from pilot drug studies. It is noteworthy that proteasome activity in
EAE animals is increased 1.6X over that in the aged-matched naïve Lewis rats, and that
calpain activity augments 5.5X over naïve rats (dashed lines in Figure 3.1).

3.4.3 Calpain inhibition increases oxidative damage to proteins in EAE
We recently reported that protein carbonylation increases in EAE Lewis rats during the
peak of disease (Smerjac & Bizzozero 2008). Previous studies investigating degradation
of oxidized protein in vitro suggested that both the proteasome and calpain show
preference for degrading carbonylated proteins (Grune et al. 1997, Troncoso et al. 1995).
We wanted to investigate whether either of these mechanisms played a role in removal of
carbonylated proteins in the spinal cords of EAE animals. The presence of protein
carbonyls in the spinal cord tissue in i.t. injected EAE rats was investigated using the
oxyblot technique.

A representative western blot detecting protein carbonyls (i.e.,

oxyblot) of 4 vehicle-, 3 calpeptin-, and 3 epoxomicin-injected EAE spinal cords is
shown in Figure 3.2A. There is a build-up of protein carbonyls in all EAE animals
compared to naïve animals, and in the calpeptin-injected EAE animals there is a clear
increase in the carbonyl content of several protein bands relative to vehicle-treated EAE.
Quantitative analysis of the oxyblots revealed that total protein carbonyl levels in
calpeptin-treated EAE spinal cords increased by 251% relative to vehicle-treated EAE
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spinal cords (Figure 3.2B). No significant increase in total protein carbonyls was seen in
epoxomicin-treated EAE, although the intensity of some bands are clearly higher. The
above results suggest that calpain acts as a clearance mechanism to eliminate these
damaged proteins in the disease tissue.

3.4.4 Intrathecal calpeptin injection reduces degradation of cytoskeletal proteins during
the peak of EAE
Previous studies in our lab showed that the integrity of CNS neuronal cytoskeletal
network in the spinal cord of EAE rats is greatly compromised. There are significantly
lower levels of NFH, NFM, NFL, and β -tubulin in EAE compared to CFA-treated
controls. This study investigated whether inhibition of calpain or the proteasome could
prevent this degradation.

We used western blotting to measure the levels of these

proteins in spinal cord homogenates. Figure 3.3A shows representative western blots of
the three neurofilament chains and β-tubulin in the spinal cord of i.t. injected EAE rats.
Figure 3.3B depicts the level of these proteins in each of the i.t. treatment groups relative
to the levels in 4 non-EAE control animals (dotted line at 100%). As previously reported
in our lab the disappearance of cytoskeletal proteins, which are metabolically very stable
(Li & Black 1996, Nixon & Logvinenko 1986), points toward increased degradation of
these proteins rather than diminished synthesis. NFL degradation has been reported by
other groups and is believed to be indicative of increased calpain activity in EAE spinal
cord. (Shields & Banik 1998). In this study we found that a single i.t. injection with the
calpain inhibitor calpeptin at the onset of neurologic symptom significantly prevents
degradation of all three neurofilament chains and β -tubulin in the spinal cord of EAE
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animals. In contrast, proteasome inhibition does not appear to prevent the clearance of
these proteins.

3.4.5 Oxidation levels of cytoskeletal proteins are not altered by partial inhibition of
proteasome or calpain
We next set out to investigate whether there are changes in the specific oxidation
(percentage of total protein modified by carbonylation) in EAE animals treated with
calpain or proteasome inhibitors. An increase in specific oxidation upon treatment with
an inhibitor would support previous in vitro studies that suggest calpain (Troncoso et al.
1995) or the proteasome (Grune et al. 1997, Poppek & Grune 2006) preferentially target
oxidized proteins for degradation. Quantification of the extent of oxidation of these
species was performed by the pull-down/western blot procedure. To this end, protein
carbonyls from i.t.-injected EAE spinal cord homogenates were first converted into
biotinylated residues by reaction with biotin-hydrazide. Biotin-containing proteins were
then isolated with streptavidin-agarose and analyzed by western blotting employing
antibodies against the three neurofilament chains and β -tubulin. Specific oxidation
(percentage of total protein modified by carbonylation) for the individual proteins were in
the following ranges: NFH, 0.48% - 3.78%; NFM, 0.06% - 0.81%; NFL, 0.004% 0.14%; β -tubulin, 0.04% - 0.63%. Although the percentage of carbonylated protein is
low, even moderate increases in the carbonylation can have tremendous effects on protein
function, aggregate formation, or metabolic stability. Figure 3.4 shows specific oxidation
of the neurofilaments and β -tubulin in the three injection groups expressed as a
percentage of the average vehicle-injected EAE animals.

We found no significant

differences in the specific oxidation of any of these proteins after treatment with
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calpeptin compared to vehicle-injected EAE animals. Epoxomicin inhibition of the
proteasome only showed a significant increase in the percentage of oxidized NFM. Thus,
although calpain is the major degradation pathway for these cytoskeletal proteins, these
in vivo studies do not support the idea that oxidized cytoskeletal proteins are
preferentially targeted toward degradation by calpain in the spinal cord at the peak of
EAE disease. Although the proteasome is not the primary pathway for degradation of
cytoskeletal proteins, it may contribute to the degradation of oxidized NFM.

3.5 Discussion
We have previously shown that cytoskeletal proteins are degraded in the spinal cords of
EAE Lewis rats and the proportion of carbonylated NFL decreases throughout the disease
course (Smerjac & Bizzozero 2008).

We hypothesized there could be a clearance

mechanism for these cytoskeletal proteins that specifically targets the oxidized proteins
for degradation.

To investigate this possibility we chose to inhibit two protein

degradation pathway that have been proposed to specifically target carbonylated proteins:
calpain and the 20S proteasome. The specific inhibitors calpeptin and epoxomicin were
delivered directly into the spinal cord at the T12 – L1 junction using intrathecal injection.
Pilot studies proved this drug delivery method to be far superior to i.p. injections used by
other groups at inhibiting calpain or the proteasome for a sustained period after a single
injection. Using this method we were able to reduce calpain activity by ~22% using
calpeptin and proteasome activity by ~24% using epoxomicin, as measured with
fluorescence-based protease activity assays in the spinal cord tissue after sacrifice.
Although calpain and proteasome inhibitors have been used to improve clinical disease in
EAE Lewis rats (Hassen et al. 2006, Hosseini et al. 2001, Vanderlugt et al. 2000), we
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found that acute treatment with inhibitors starting at the first sign of clinical disease did
not alter the disease course. It was critical to our experimental paradigm that we were
able to inhibit these proteases without altering the disease course, so differences seen in
protein oxidation and cytoskeletal degradation could be attributed to the differences in
enzyme activity and not disease severity.
We then showed that this modest inhibition of calpain early in the clinical disease
led to increased accumulation of total protein carbonyls, as measured by oxyblot.
Degradation of the neurofilament proteins and β-tubulin was also significantly reduced in
the animals with inhibited calpain activity.

However, we were unable to detect

significant changes in the specific carbonylation of these particular cytoskeletal proteins.
Thus, we conclude that while calpain is an important degradation mechanism for
cytoskeletal proteins, it does not preferentially remove carbonylated neurofilaments or
tubulin at a faster rate than it degraded the non-oxidized cytoskeletal elements.
Approaching the question of the role of the proteasome in cytoskeletal degradation and
oxidation, we found proteasomal inhibition did not lead to changes in total carbonylation
or degradation, but does increase the specific oxidation of NFM proteins. The increase
seen in total protein oxidation after treatment with calpain inhibitors is most likely due to
the lower amount of overall protein degradation. With decreased proteolysis there are
more neurofilament and tubulin, which are major oxidized species, and the overall
increase in carbonylation reflects the increased presence of these, and potential other
unidentified, carbonylated proteins molecules. The increase seen in oxidized NFM after
proteasome inhibition supports the idea that the proteasome may contribute to removal of
carbonylated neurofilament even though calpain is clearly the principal degradation

63

mechanism of this protein. This is the first study, to our knowledge, to investigate the
specific targeting of carbonylated proteins for degradation by the proteasome or calpain
in vivo.
We have previously reported that there is a change in the specific oxidation of
NFL throughout the disease course and hypothesized that this was due to preferential
degradation of oxidized proteins by either calpain or the proteasome (Smerjac &
Bizzozero, 2008). Another potential explanation for the lower percentage of oxidized
NFL molecules later in the disease course is that cytoskeletal digestion could trigger
synthesis of new NFL proteins to replace the degraded molecules, which aids in the
neurological recovery seen in this acute EAE model. Oxidative damage accumulates in
organisms as they age (Stadtman & Berlett 1998), and therefore proteins with slow
turnover rates are more likely to have oxidative modifications like carbonylation. Newly
synthesized NFL molecules would be less likely to have oxidative modifications, thereby
decreasing the specific carbonylation of the particular protein. The presence of newly
synthesized, non-oxidized proteins diluting the total protein pool is a reasonable
explanation for the decrease in specific oxidation of certain cytoskeletal proteins seen
during the EAE disease course.
Our findings suggest that preferential degradation of carbonylated proteins is not
a contributing factor in cytoskeletal removal.

It is, however, important to consider the

limitations of our experiment, which approached this question in an in vivo system by
treating animals with inhibitors. We achieved a 22% decrease in calpain activity and a
24% decrease in proteasome activity in spinal cord tissue after direct intrathecal injection.
These reductions in enzyme activity are significant, and led to considerable biochemical
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changes in protein oxidation and cytoskeletal degradation. However, in this system we
could not achieve higher levels of inhibition even with 10x doses of calpeptin or
epoxomicin, or using other proteasome and calpain inhibitors (data not shown). It must
be considered that the remaining active calpain or proteasome could be sufficient to
preferentially remove oxidized proteins from the cell. Additionally, we chose to focus on
neurofilaments and tubulin, which we demonstrated previously to be some of the major
targets of oxidation and degradation in the cell, but it is possible that investigating
specific oxidation levels of other carbonylated proteins after proteasome or calpain
inhibition could identify proteins that do have increased susceptibility to degradation.
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3.8 Tables and Figures

Table 3.1 Characteristics of disease in EAE animals in inhibitor treatment groups
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Figure 3.1. Proteasome and calpain activity in inhibitor-treated EAE spinal cord.

EAE was induced in Lewis rats; upon first signs of clinical disease (9-11DPI) animals
were injected intrathecally with the proteasome inhibitor epoxomicin (n = 9) dissolved in
4 µL DMSO, the calpain inhibitor calpeptin (n = 11) dissolved in 5 µL DMSO, or with
the vehicle DMSO alone (n = 15). Spinal cord segments L1 - L3 were dissected and
homogenized in HEN buffer 48 hours after i.t. injection. (A) Chymotrypsin-like activity
of the 20S proteasome was measured as described in “Materials and Methods.” (B)
Calpain activity in spinal cord tissue was measured as described in “Materials and
Methods.” Values are expressed as a percentage of the average vehicle-treated value.
Proteasome and calpain activity was analyzed for statistical significance to determine
difference from vehicle-injected EAE animals using unpaired t-test, (*) p<0.05. There
was a significant reduction in calpain activity for calpeptin- compared to vehicle- injected
rats; t(24)=2.530, p=0.018. Epoxomicin injection significantly reduced proteasome
activity; t(22)=2.233, p=0.036. Dotted lines represent the average proteasome or calpain
activity from 4 age-matched uninjected non-EAE Lewis rats.
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Figure 3.2. Protein carbonyls in the spinal cord of EAE rats accumulate after treatment with a
calpain inhibitor.

Spinal cord proteins (5 µg) from i.t. injected EAE animals were separated by SDS-PAGE.
Carbonylated proteins were determined using western blotting as described in “Materials
and Methods”. (A) Representative oxyblot showing four vehicle-, three calpeptin-, and
three epoxomicin-injected EAE animals sacrificed 48 hours after i.t. injection. (B) Protein
carbonyl values, epoxomicin-injected, n = 9 and calpeptin-injected, n = 11, are expressed
as a percentage of the average carbonylation in vehicle-injected EAE spinal cords (n =
15). Dotted lines represent the average protein carbonylation from 4 age-matched
uninjected non-EAE Lewis rats. Data was analyzed for statistical significance from that
of vehicle-injected EAE animals using unpaired t-test, (*) p<0.05. There was a significant
difference in overall protein carbonylation for calpeptin- and vehicle-injected conditions;
t(24)=2.240, p = 0.035.
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Figure 3.3. Levels of cytoskeletal proteins in i.t.-injected EAE spinal cords.

Spinal cord proteins (5 µg) from i.t.-injected EAE animals were separated by SDS-PAGE
followed by western blotting. Membranes were immunostained with antibodies against
four cytoskeletal proteins (3 neurofilament chains and β-tubulin). (A) Representative
western blot samples from 3 vehicle-, 3 calpeptin- and 3 epoxomicin-treated EAE rats.
(B) Mean levels of each cytoskeletal protein were tracked throughout the disease course,
epoxomicin-, n = 9, calpeptin-, n = 11, and vehicle-injected, n = 15. Values are
expressed as a percentage of the average protein level compared to 4 uninjected non-EAE
control spinal cords (dotted line at 100%). Data was analyzed for statistical significance
from that in vehicle-injected EAE animals using unpaired t-test, (**) p<0.01, (***)
p<0.001. Calpain inhibition significantly prevented the degradation of NFH; t(24)=4.299,
p=0.000, NFM; t(24)=4.939, p=0.000, NFL; t(24)=3.875, p=0.001, β-tubulin;
t(24)=2.879, p=0.008, compared to treatment with the DMSO vehicle. Treatment with
epoxomicin did not affect neurofilament or β-tubulin levels.
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Figure 3.4. Specific oxidation of cytoskeletal protein in i.t.-injected EAE spinal cords.

Spinal cord proteins were derivatized with biotin hydrazide and carbonylated proteins
were isolated with streptavidin-agarose as described in Materials and Methods. Total and
bound fractions were analyzed by SDS-PAGE followed by western blotting for four
cytoskeletal proteins (3 neurofilament chains, and β-tubulin). Specific oxidation
(percentage of total protein modified by carbonylation) for the individual proteins are
reported for the individual treatment groups, epoxomicin-, n = 9, calpeptin-, n = 10, and
vehicle-injected, n = 13, and expressed as a percentage of the vehicle-injected EAE
animals. Data was analyzed for statistical significance using unpaired t-test, (*) p<0.05.
A significant increase the amount of oxidized NFM; t(20)=2.785, p=0.011, was seen
upon treatment with the proteasome inhibitor epoxomicin. No changes in specific
oxidation of these four proteins were observed upon treatment with calpain inhibitors.
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4. General Discussion
4.1 Oxidative stress and its role in metabolic stability of proteins in EAE
Multiple sclerosis (MS) is an inflammatory disease of the CNS leading to demyelination
and axonal damage (Trapp et al. 1998). EAE is a widely employed animal model, which
has a number of clinical features analogous to MS (Gold et al. 2000). A significant body
of experimental evidence has accumulated suggesting that oxidative stress is a major
player in the pathogenesis of inflammatory demyelination. Generation of ROS in vivo has
been inferred from (1) the presence of the lipid peroxidation products malondialdehyde
(Hunter et al. 1985, Calabrese et al. 1994, Naidoo & Knapp 1992) and isoprostanes
(Greco et al. 1999) in the cerebrospinal fluid (CSF) and plasma of MS patients, (2)
reduced plasma levels of antioxidants (e.g., ubiquinone, vitamin E) (Shukla et al. 1977)
and antioxidant enzymes (e.g., catalase and glutathione peroxidase) (LeVine 1992) in
MS, (3) low levels of antioxidants like glutathione, α-tocopherol and uric acid in MS
plaques (Langemann et al. 1992), and (4) the damage to mitochondrial DNA in active
chronic plaques (Vladimirova et al. 1998). In addition to accumulation of oxidized
macromolecules and reduction of antioxidants, MS and EAE are characterized by
dysregulation of transition metals like iron (LeVine 1997) and copper (Melo et al. 2003),
which promote oxidative damage via the Fenton and Haber-Weiss reactions (Lewen et al.
2000). Additional evidence for a pathogenic role of ROS comes from the effectiveness of
various antioxidant treatments at ameliorating EAE. For example, oral administration of
the oxidant-scavenger N-acetylcysteine, which raises intracellular glutathione levels,
inhibits the induction of acute EAE (Lehmann et al. 1994). Therapeutic success in the
treatment of EAE has also been reported with other antioxidants such as α-lipoic acid
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(Marracci et al. 2002), bilirubin (Liu et al. 2003), uric acid (Hooper et al. 1998) and
flavonoids (Hendriks et al. 2004). Administration of antioxidant enzymes like
metallothionein (Penkowa & Hidalgo 2003), catalase (Ruuls et al. 1995) and synthetic
catalytic scavengers with combined superoxide dismutase and catalase activity (Malfroy
et al. 1997) were found to be effective as well. Likewise, chelation of the pro-oxidant
iron with deferoxamine (Pedchenko & LeVine 1998) and copper with N-acetylcysteine
amide (Offen et al. 2004) has been shown to reduce tissue damage and improve the
clinical course of EAE. Most relevant to the current study are the findings that protein
carbonyls accumulate in brain tissue of MS patients (Bizzozero et al. 2005b) and that of
EAE mice (Zheng & Bizzozero 2010a), and that cytoskeletal proteins are major targets of
carbonylation in these diseases (Bizzozero 2007). The objectives of this thesis were to
(1) characterize oxidative stress conditions in acute EAE, identifying the major protein
targets of oxidation and (2) examine the proteolytic mechanisms responsible for
clearance of oxidized proteins during the inflammatory phase of EAE.
In this study I have characterized oxidative stress conditions that occur in MBPinduced EAE in the Lewis rat by measuring established markers for oxidative damage
throughout the disease course. I discovered that the concentration of free GSH in the
spinal cord of EAE rats is greatly decreased at 10-11 DPI. GSH levels return to normal
values as inflammation subsides and animals recover after 13 DPI. Acute depletion of
GSH in brain slices leads to oxidative stress sufficient to induce protein carbonylation
(Bizzozero et al. 2006).
TBARS assay, the most commonly used measurement for lipid peroxidation,
detects dialdehydes (mostly MDA) resulting from breakdown of lipid hydroperoxides and
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endoperoxides (Esterbauer et al. 1991). These dialdehyde lipid peroxidation products are
reactive carbonyl species (RCS) and can react with proteins to induce protein carbonyls.
In contrast to the reduction of GSH levels, which parallels disease activity, the
concentration of TBARS in the EAE spinal cords is elevated at every time point
measured (i.e., 7-15 DPI). This result indicates that the oxidative stress takes place prior
to the appearance of inflammatory lesions in the spinal cord of EAE animals, a
pathological process that correlates temporally with neurological symptoms (Schaecher et
al. 2002). The presence of TBARS in 15 DPI animals, which are recovering
neurologically, may be due to continued ROS generation or more likely to the persistence
of dialdehydes in the tissue (MDA t½ = 2 days) (Aldini et al. 2007).
One of the most important finding in this study is that several carbonylated
protein species accumulate in the spinal cord of EAE rats at 11–13 DPI. The degree and
distribution of protein carbonylation present during autoimmune neuroinflammation
indicates that the oxidative stress conditions in this model are very severe. It is believed
that the accumulation of carbonylated proteins is a multifaceted process that takes into
account both the rate of oxidation (dependent on both ROS formation and antioxidant
levels) and the rate of proteolysis of the damaged proteins (Sayre et al. 2005). In this
acute animal model of MS there appears to be a mechanism that eliminates these
damaged proteins and bring carbonylation to control levels as the inflammatory process
subsides. Other work in our laboratory in female C57/BL6 EAE mice, which exhibit an
acute and chronic phase of disease, also display increased protein carbonyls, localized
primarily to cerebellar astrocytes in the vicinity of inflammatory regions, during the acute
phase (Zheng & Bizzozero 2010a). Since ROS have variable but still relatively short
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half-lives (10-9 s for hydroxyl radicals, 10-6 s for superoxide, 10-3 s for peroxynitrite, 100 s
peroxyl radicals and 102 s for hydrogen peroxide) (Reth 2002), they normally damage
targets that are in close proximity to their source. Thus, if ROS in EAE spinal cords were
generated mostly by inflammatory cells, one would expect to find accumulation of
protein carbonyls near the inflammatory foci, as seen in acute EAE mice cerebellum
(Zheng & Bizzozero 2010a). Instead, I discovered that protein carbonyls are not
circumscribed to inflammatory lesions but accumulate throughout the spinal cord. This
more generalized carbonyl increase, staining multiple cell types including neurons,
suggests that the origin of ROS is likely metabolic, although other cellular/subcellular
sources of ROS cannot be excluded. Supporting this idea are the facts that (1) there is
mitochondrial damage and augmented superoxide production in EAE and MS (Kalman et
al. 2007) and (2) protein carbonyls do not increase until after the antioxidant glutathione
is depleted. In this model, mitochondrial dysfunction and the resulting intracellular ROS
production is likely triggered by glutamate excitotoxicity and calcium influx, which also
activate calpain, found in this study to be the major proteolytic mechanism for
cytoskeletal protein removal.

The lack of protein carbonylation in the presence of

sustained RCS production is noteworthy and suggests that carbonylation of proteins in
EAE takes place via a direct mechanism and not indirectly by reaction with RCS (MDA,
4-HNE glyoxal, methyl glyoxal). In this regard, our group has recently found that, while
dependent on lipid peroxidation, the carbonylation of cytoskeletal proteins during
depletion of glutathione probably occurs via lipid hydroperoxides rather than RCS
(Bizzozero et al. 2007). Furthermore, western blot analysis of CNS proteins using
specific antibodies against RCS showed that the amount of MDA-, acrolein- and 4-HNE-
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protein adducts does increase neither upon GSH depletion (Zheng & Bizzozero 2010c)
nor during the course of MOG-induced EAE in C57/BL6 mice (Zheng & Bizzozero
2010a).
Another major finding in this study is the identification of neurofilaments, β tubulin, β-actin and GFAP as targets of carbonylation in EAE. Interestingly, it was also
observed that there is a gradient in the carbonylation of NF proteins with NFH being the
most heavily oxidized and NFL having the lowest specific oxidation. This may be due to
the structure of the intermediate filament in which NFL forms the filament core and NFH
and NFM are more peripherally located making them more susceptible to attack by ROS
(Tsuda et. al. 2000) as well as the presence of more carbonylation-susceptible amino acid
sequences in NFH compared to NFM and NFL (see Appendix C). Cytoskeletal proteins
are established targets of protein carbonylation in many diseases including several CNS
disorders (Aksenov et al. 2001, Muntane et al. 2006), and oxidative damage to these
proteins is known to have deleterious effects on the macromolecule structures. For
instance, actin filaments and microtubules both destabilize and disassemble upon
oxidation of their protein components (Banan et al. 2001, Banan et al. 2004, Dalle-Donne
et al. 2001, Neely et al. 2005, Ozeki et al. 2005).

The secondary structure of

neurofilaments is also altered when the individual proteins become carbonylated (Gelinas
et al. 2000), often leading to the formation of dense aggregates (Smith et al. 1995). I have
demonstrated that neurofilament proteins and β -tubulin are extensively degraded in the
EAE spinal cord, which likely causes alterations in the cytoskeletal network. I have also
observed that the specific oxidation of NFL protein decreases in EAE, suggesting the
possibility that oxidized neurofilament may be preferentially degraded in this disease. It

78

is well known that proteolysis of carbonylated proteins in cells under conditions of
oxidative stress aids in preventing formation of large aggregates that could be cytotoxic
(Davies & Shringarpure 2006, Shringarpure et al. 2001). Identifying the triggers for
neurofilament degradation may help us to understand the mechanisms of axonal
degeneration during neuroinflammation in acute EAE.
Whether calpain, the proteasome, or a combination of these proteolysis pathways
is responsible for the degradation of carbonylated neurofilament proteins in EAE was the
focus of chapter 3. The 20S proteasome has been shown to selectively recognize and
degrade oxidized proteins (Grune et al. 1995, Pacifici et al. 1993, Rivett 1985), and upon
its inhibition carbonylated proteins do indeed accumulate (Lee et al. 2001). Calpain is
also believed to be responsible for neurofilament degradation in EAE (Shields & Banik
1998), but it is unclear if this calcium-activated protease has preference for oxidized over
native polypeptides. Previous studies using proteasome and calpain inhibitors in EAE
have primarily focused on abatement of neurological symptoms without looking at
specific proteins that are protected from proteolysis (Guyton et al. 2005, Hassen et al.
2008, Hosseini et al. 2001, Vanderlugt et al. 2000).
In this study I used a single i.t. injection of the proteasome inhibitor epoxomicin
or the calpain inhibitor calpeptin to inhibit these proteolytic pathways for 48 hours at the
onset of clinical symptoms. I showed that a modest inhibition of calpain 48 hours early
in clinical disease leads to increased accumulation of total protein carbonyls, as measured
by oxyblot.

Degradation of the neurofilament proteins and β -tubulin was also

significantly reduced in the animals with inhibited calpain activity. However, I was
unable to detect significant changes in the specific carbonylation of these particular
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cytoskeletal proteins. Thus, I conclude that while calpain is an important degradation
mechanism for cytoskeletal proteins, it does not preferentially remove carbonylated
neurofilaments or tubulin at a faster rate than it degraded the non-oxidized cytoskeletal
elements.

Approaching the question of the role of the proteasome in cytoskeletal

degradation and oxidation, I found proteasomal inhibition did not lead to changes in total
carbonylation or degradation of these proteins. There was an increase in the percent of
oxidized NFM with proteasome inhibition, indicating that the proteasome may contribute
to removal of oxidized neurofilament even though calpain is clearly the primary
mechanism for degradation of those proteins.
The increase seen in total protein oxidation after treatment with a calpain inhibitor
is most likely due to the lower amount of protein degradation overall. With decreased
proteolysis there are more neurofilament and tubulin, which are major oxidized species,
and the overall increase in carbonylation reflects the increased presence of these, and
potentially other unidentified, carbonylated proteins molecules. In chapter 2, I reported
that there is a change in the specific oxidation of NFL throughout the disease course and
hypothesized that this was due to preferential degradation of oxidized proteins by either
calpain or the proteasome (Smerjac & Bizzozero 2008). Another potential explanation
for the lower percentage of oxidized NFL molecules later in the disease course is that
cytoskeletal digestion could trigger synthesis of new NFL proteins to replace the
degraded molecules, which would contribute to the neurological recovery seen in this
acute EAE model. Oxidatively damaged proteins accumulate in organisms as they age
(Stadtman & Berlett 1998), and therefore proteins with slow turnover rates are more
likely to have oxidative modifications like carbonylation.
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Newly synthesized NFL

molecules would be less likely to have oxidative modifications, thereby decreasing the
specific carbonylation of the particular protein (Figure 4.1). The presence of newly
synthesized, non-oxidized proteins diluting the total protein pool is a logical explanation

for
the 4.1
decrease
infactors
specific
oxidation
certain
proteins
seen during
Figure
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contrast, during the chronic phase in the murine EAE model carbonylation levels are
much higher than those seen in the acute rat model and there are 2-5 fold increases in the
proportion of cerebellar GFAP, β-actin, and β-tubulin that are carbonylated in the chronic
phase compared to the acute phase (Zheng & Bizzozero 2010a). This increase is believed
to be a result of impaired proteasomal activity during chronic EAE (Zheng & Bizzozero
2010b). Proteasomal activity in this acute model in Lewis rats is increased during the
disease.

This disparity highlights the various factors contributing to carbonyl

accumulation during different phases of these myelin-directed neuroinflammatory
disorders.
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The clinical implications of this study are twofold. First, the discovery that there
are likely significant sources of metabolic ROS during acute neuroinflammation provides
insights into mechanisms that contribute to oxidative cellular damage in MS. When
carbonyls accumulate in the CNS the damage to proteins can result in cross-linking and
the formation of high molecular weight aggregates that are resistant to proteolysis. This
aggregate formation may impair neuronal signaling and contribute to neurological
disability seen in advanced stages of the disease. Potential therapies focused on reducing
mitochondrial oxidants may help to prevent oxidative protein damage improving or
delaying progressive disease activity. Second, in this work I have identified calpain as
the

major

proteolytic

mechanisms

for

cytoskeletal

degradation

during

neuroinflammation. Degradation of the neuronal cytoskeleton, especially neurofilaments,
coincides with axonal damage, which is believed to be responsible for the progressive
neurologic impairments seen in secondary-progressive MS. Acute treatment with calpain
inhibitors during the peak of neuroinflammatory activity, even after the onset of
symptoms, was able to significantly prevent degradation of the neuronal cytoskeleton.
Reducing cytoskeletal proteolysis during inflammatory attacks may offer a therapeutic
strategy to impede axonal damage, thereby reducing or delaying the onset of progressive
neurologic disability seen in the later disease stages.

4.2 Limitations of the experimental model and future directions
Our findings suggest that preferential degradation of carbonylated proteins by calpain or
the proteasome is not a contributing factor to the decrease in specific oxidation of NFL.
It is, however, important to consider the limitations of our experiment, which approached
this question in an in vivo system by treating animals with inhibitors. I achieved a 22%

82

decrease in calpain activity and a 24% decrease proteasome activity in EAE spinal cord
tissue after direct intrathecal injection. This reduction in calpain enzyme activity is
significant, and led to considerable biochemical changes in protein oxidation and
cytoskeletal degradation. However, in this system I could not achieve higher levels of
inhibition of either proteolytic system even with 10x doses of calpeptin or epoxomicin, or
using other proteasome and calpain inhibitors (data not shown). It must be considered
that remaining active calpain or proteasome could be sufficient to preferentially remove
oxidized proteins from the cell.

When considering that the proteasome activity is

increased 1.6 fold and calpain is 5.5 times more active in EAE over naïve rats, it is
possible that even with this reduction in activity there is still adequate amounts of active
proteasome or calpain to clear damaged proteins from the cells.
The protocol that I utilized for i.t. injection of inhibitor used a single injection. It
would be interesting to explore the effect of a sustained delivery of these calpain or
proteasome inhibitors. One possibility would be to use an indwelling spinal catheter
allowing for multiple inhibitor injections in the same animal. Indwelling spinal catheters
for drug delivery in rats are routinely employed in a variety of experimental paradigms
including MOG-induced EAE in Dark Agouti rats (Ramos et al. 2010). This approach
would require surgery to place the catheter at least one week prior to disease onset.
Extensive control experiments would be required to work out doses of inhibitors and
determine whether spinal catheter placement influences oxidative stress and cytoskeletal
proteolysis in EAE Lewis rats since i.t. catheterization alone is known to induce immune
responses in the spinal cord, including cytokine induction, microglia and astrocyte
activation (DeLeo et al. 1997).
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Additionally, we chose to focus on neurofilaments and tubulin, which I
demonstrated previously to be some of the major targets of oxidation and degradation in
the cell, but it is possible that investigating specific oxidation levels of other carbonylated
proteins after proteasome or calpain inhibition could identify proteins that do have
increased susceptibility to degradation in this model. Two-dimensional oxyblots could be
used to isolate protein spots that show significant changes in oxidation levels after
treatment with inhibitors. After identification of the proteins by mass spectrometry, I
could use the biotin-hydrazide pull-down followed by western blotting to measure
changes in the specific oxidation of those proteins and to confirm changes seen in the 2D
oxyblot.
Finally, experiments are underway in our lab to confirm the in vivo findings in a
cell culture system.

These experiments are using glutathione depletion to trigger

oxidative stress and induce protein carbonyls in cultured neurons, which will then be
treated with calpeptin and epoxomicin to inhibit calpain or the proteasome. To date,
degradation of oxidized neurofilament proteins has only been investigated in cell-free
systems (Troncoso et al. 1995). Determining proteolytic mechanisms for removal of
carbonylated neurofilaments in cell culture, combined with the results from this in vivo
study, will help to clarify the contribution of the proteasome and calpain to proteolysis of
neurofilament proteins and help elucidate the role of protein carbonylation in axonal
damage.
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4.3 Scientific impact
This study was the first to identify oxidation of the neuronal cytoskeleton during
acute

phase

of

autoimmune

neuroinflammation.

Furthermore,

the

ubiquitous

accumulation of oxidized proteins in various cell types and far from inflammatory lesions
suggests severe oxidative stress not just from monocyte-derived ROS, but from metabolic
sources as well. The cytoskeletal proteins that are carbonylated in EAE are also major
oxidized molecules observed in MS patients. Identifying this type of damage to these
proteins in an animal model will allow elucidation of mechanisms contributing to axonal
damage in MS. This is also the first study, to our knowledge, to investigate the specific
targeting of carbonylated proteins for degradation by the proteasome or calpain in vivo.
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Appendix A
Figure A.1 NFM immunofluorescence in Control and EAE ventral horn region of lower thoracic
spinal cord sections (10x and 32x) with DAPI counterstain.

Using immunofluorescence to look at the neurofilament network in EAE animals I was
able to detect an altered staining pattern for NFM. This figure shows IHC for NFM in
control and EAE spinal cord cross sections. In the 10x imaged you can see heavy
staining in the cell bodies in EAE whereas the control animals show a more even
neurofilament distribution. At 20x there NFM staining in EAE is more punctate than the
normal filamentous staining seen in the control spinal cords, suggesting the possible
formation of axonal ovoid bodies. Overall these images suggest alterations in the
neurofilament network including changes in the axonal distribution of the proteins. The
heavy staining in the cell body possibly points to an increase in newly synthesized
neurofilament that has not yet been transported down the axons.
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Appendix B
Figure B.1 Triton insoluble fraction of cytoskeletal proteins in CFA-injected control and EAE spinal
cords.

Changes in the distribution (assembled vs. disassembled) of cytoskeletal protein during
the course of EAE. Carbonylation can lead to depolymerization of the cytoskeletal
structures, so lower proportions of specific proteins may be found in the Triton insoluble
(assembled) cytoskeletal fraction. At 13 DPI there is significantly more disassembled
NFM, NFL, β – tubulin. This suggests that at the peak of disease there is disassembly of
the cytoskeleton and that damage may be contributing to the degradation of those
proteins. Because there is also more disassembled GFAP, which is not degraded in EAE,
at 13 DPI, there is likely to be increased synthesis of these proteins, as well, which have
not yet become incorporated into filaments.
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Appendix C
Direct metal-catalyzed oxidation attacks on the amino-acid side chains of proline (P),
arginine (R), lysine (K) and threonine (T) form the majority of carbonyl derivatives. The
rules governing sites that are highly susceptible to carbonylation are complex, but one
predictive measure is the presence of an RKPT- enriched region, defined by the presence
of at least 3 carbonylatable amino acids within a 4 amino acid sequence window
(Maisonneuve et al. 2009). Mass spectrometry analysis of bovine serum albumin and 23
carbonylated proteins in Escherichia coli show that amino acids located within RKPTenriched regions are approximately 4 times more prone to oxidation than those external
to these regions. Sequence analysis of the three rat neurofilament chains for RKPTenriched regions reveal that NFH contain 28-, NFM has 15-, and NFL has 5- RKPTenriched regions (Figures C.1., C.2., and C.3.). This analysis supports my observation
that the specific oxidation of the neurofilaments follows the gradient where carbonylation
of NFH > NFM > NFL.

Figure C.1. Neurofilament heavy chain protein sequence with the 28 amino acid sequences that are
highly susceptible to carbonylation underlined.
10
20
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60
MMSFGSADAL LGAPFAPLHG GGSLHYALSR KAGAGGTRSA AGSSSGFHSW ARTSVSSVSA
70
80
90
100
110
120
SPSRFRGAAS STDSLDTLSN GPEGCVAAVA ARSEKEQLQA LNDRFAGYID KVRQLEAHNR
130
140
150
160
170
180
TLEGEAAALR QQKGRAAMGE LYEREVREMR GAVLRLGAAR GHVRLEQEHL LEDIAHVRQR
190
200
210
220
230
240
LDEEARQREE AEAAARALAR FAQEAEAARV ELQKKAQALQ EECGYLRRHH QEEVGELLGQ
250
260
270
280
290
300
IQGCGAAQAQ AQAEARDALK CDVTSALREI RAQLEGHTVQ STLQSEEWFR VRLDRLSEAA
310
320
330
340
350
360
KVNTDAMRSA QEEITEYRRQ LQARTTELEA LKSTKESLER QRSELEDRHQ VDMASYQDAI
370
380
390
400
410
420
QQLDNELRNT KWEMAAQLRE YQDLLNVKMA LDIEIAAYRK LLEGEECRIG FGPSPFSLTE
430
440
450
460
470
480
GLPKIPSMST HIKVKSEEKI KVVEKSEKET VIVEEQTEEI QVTEEVTEEE DKEAQGEEEE
490
500
510
520
530
540
EAEEGGEEAA TTSPPAEEAA SPEKETKSPV KEEAKSPAEA KSPAEAKSPA EAKSPAEVKS
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550
560
570
580
590
600
PAEVKSPAEA KSPAEAKSPA EVKSPAEVKS PAEAKSPAEA KSPAEVKSPA TVKSPGEAKS
610
620
630
640
650
660
PAEAKSPAEV KSPVEAKSPA EAKSPASVKS PGEAKSPAEA KSPAEVKSPA TVKSPVEAKS
670
680
690
700
710
720
PAEVKSPVTV KSPAEAKSPV EVKSPASVKS PSEAKSPAGA KSPAEAKSPV VAKSPAEAKS
730
740
750
760
770
780
PAEAKPPAEA KSPAEAKSPA EAKSPAEAKS PAEAKSPVEV KSPEKAKSPV KEGAKSLAEA
790
800
810
820
830
840
KSPEKAKSPV KEEIKPPAEV KSPEKAKSPM KEEAKSPEKA KTLDVKSPEA KTPAKEEAKR
850
860
870
880
890
900
PADIRSPEQV KSPAKEEAKS PEKEETRTEK VAPKKEEVKS PVEEVKAKEP PKKVEEEKTP
910
920
930
940
950
960
ATPKTEVKES KKDEAPKEAQ KPKAEEKEPL TEKPKDSPGE AKKEEAKEKK AAAPEEETPA
970
980
990
1000
1010
1020
KLGVKEEAKP KEKAEDAKAK EPSKPSEKEK PKKEEVPAAP EKKDTKEEKT TESKKPEEKP
1030
1040
1050
1060
1070
KMEAKAKEED KGLPQEPSKP KTEKAEKSSS TDQKDSQPSE KAPEDKAAKG DK

Figure C.2. Neurofilament medium chain protein sequence with the 15 amino acid sequences that
are highly susceptible to carbonylation underlined.

10
20
30
40
50
60
MSYTLDSLGN PSAYRRVPTE TRSSFSRVSG SPSSGFRSQS WSRGSPSTVS SSYKRSALAP
70
80
90
100
110
120
RLAYSSAMLS SAESSLDFSQ SSSLLNGGSG GDYKLSRSNE KEQLQGLNDR FAGYIEKVHY
130
140
150
160
170
180
LEQQNKEIEA EIHALRQKQA SHAQLGDAYD QEIRELRATL EMVNHEKAQV QLDSDHLEED
190
200
210
220
230
240
IHRLKERFEE EARLRDDTEA AIRAVRKDIE ESSMVKVELD KKVQSLQDEV AFLRSNHEEE
250
260
270
280
290
300
VADLLAQIQA SHITVERKDY LKTDISTALK EIRSQLECHS DQNMHQAEEW FKCRYAKLTE
310
320
330
340
350
360
AAEQNKEAIR SAKEEIAEYR RQLQSKSIEL ESVRGTKESL ERQLSDIEER HNHDLSSYQD
370
380
390
400
410
420
IQQLENELR GTKWEMARHL REYQDLLNVK MALDIEIAAY RKLLEGEETR FSTFSGSITG
430
440
450
460
470
480
PLYTHRQPSV TISSKIQKTK VEAPKLKVQH KFVEEIIEET KVEDEKSEME DALTVIAEEL
490
500
510
520
530
540
AASAKEEKEE AEEKEEEPEV EKSPVKSPEA KEEEEGEKEE EEEGQEEEEE EDEGVKSDQA
550
560
570
580
590
600
EEGGSEKEGS SEKDEGEQEE EGETEAEGEG EEAEAKEEKK TEGKVEEMAI KEEIKVEKPE
610
620
630
640
650
660
KAKSPVPKSP VEEVKPKPEA KAGKDEQKEE EKVEEKKEVA KESPKEEKVE KKEEKPKDVP
670
680
690
700
710
720
DKKKAESPVK EKAVEEMITI TKSVKVSLEK DTKEEKPQQQ EKVKEKAEEE GGSEEEVGDK
730
740
750
760
770
780
SPQESKKEDI AINGEVEGKE EEEQETQEKG SGQEEEKGVV TNGLDVSPAE EKKGEDRSDD
790
800
810
820
830
840
KVVVTKKVEK ITSEGGDGAT KYITKSVTVT QKVEEHEETF EEKLVSTKKV EKVTSHAIVK
EVTQGD
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Figure C.3. Neurofilament light chain protein sequence with the 5 amino acid sequences that are
highly susceptible to carbonylation underlined.
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MSSFSYEPYF STSYKRRYVE TPRVHISSVR SGYSTARSAY SSYSAPVSSS LSVRRSYSSS
70
80
90
100
110
120
SGSLMPSLEN LDLSQVAAIS NDLKSIRTQE KAQLQDLNDR FASFIERVHE LEQQNKVLEA
130
140
150
160
170
180
ELLVLRQKHS EPSRFRALYE QEIRDLRLAA EDATNEKQAL QGEREGLEET LRNLQARYEE
190
200
210
220
230
240
EVLSREDAEG RLMEARKGAD EAALARAELE KRIDSLMDEI AFLKKVHEEE IAELQAQIQY
250
260
270
280
290
300
QISVEMDVS SKPDLSAALK DIRAQYEKLA AKNMQNAEEW FKSRFTVLTE SAAKNTDAVR
310
320
330
340
350
360
AAKDEVSESR RLLKAKTLEI EACRGMNEAL EKQLQELEDK QNADISAMQD TINKLENELR
370
380
390
400
410
420
STKSEMARYL KEYQDLLNVK MALDIEIAAY RKLLEGEETR LSFTSVGSIT SGYSQSSQVF
430
440
450
460
470
480
GRSAYSGLQS SSYLMSARAF PAYYTSHVQE EQSEVEETIE ATKAEEAKDE PPSEGEAEEE
490
500
510
520
530
540
EKEKEEGEEE EGAEEEEAAK DESEDAKEEE GGEGEEEDTK ESEEEEKKEE SAGEEQAAKK
KD
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Abbreviations Used
4-HNE

4-Hydroxynonenal

ANOVA

analysis of variance

CFA

complete Freund's adjuvant

CNS

central nervous system

DNP

2,4-dinitrophenyl

DMSO

dimethyl sulfoxide

DPI

days post immunization

DTT

dithiothreitol

EAE

experimental autoimmune encephalomyelitis

ECL

enhanced chemioluminescence

GFAP

glial acidic fibrillary protein

GM

gray matter

GSH

glutathione

HEPES

4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid

HRP

horseradish peroxidase

IHC

immunohistochemistry

i.p.

intraperitoneal

i.t.

intrathecal

MDA

malondialdehyde

MBP

myelin basic protein

MS

multiple sclerosis

NFH

neurofilament heavy (200kDa) protein

NFL

neurofilament light (69kDa) protein

NFM

neurofilament medium (150kDa) protein
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OS

oxidative stress

PAGE

polyacrylamide gel electrophoresis

PCOs

protein carbonyls

PE

polyethylene

PUFA

polyunsaturated fatty acids

PVDF

polyvinylidene difluoride

RCS

reactive carbonyl species

ROS

reactive oxygen species

SD

standard deviation

SDS

sodium dodecyl sulfate

SEM

standard error of mean

TBARS

thiobarbituric acid reactive substances

WM

white matter
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